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In many areas of innovation, the United States is a leader, but this 
characterization does not apply to the United States' position in assisted reproductive 
technology innovation and clinical use. This article uses a political science concept, the 
idea of the "democratic deficit" to examine the lack of American public discourse on 
innovations in ART. In doing so, the article focuses on America's missing public 
consultation in health care innovation. This missing discourse is significant, as political 
and ethical considerations may impact regulatory decisions. Thus, to the extent that 
these considerations are influencing the decisions of federal agency employees, namely 
those who work within the U.S. Food and Drug Administration, the public is unable to 
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participate in the decision-making process. This lack of a public discourse undermines 
the goals of the administrative state, which include democratic participation, 
transparency, and accountability. 
The United Kingdom, on the other hand, has had a markedly divergent 
experience with assisted reproductive technology innovation. Instead of ignoring the 
various ethical, social, and legal issues surrounding assisted reproductive technology 
innovation, the United Kingdom engaged in a jive-strand public consultation on the 
topic of mitochondrial transfer, a form of assisted reproductive technology that uses 
genetic modification in order to prevent disease transmission. This article argues that 
after a multi-decade standstill in terms of the public discourse related to ethical issues 
associated with assisted reproductive technology and germline modification, it is time 
for the United States to institute a more democratic inquiry into the scientific, ethical, 
and social implications of new forms of assisted reproductive technology and ultimately, 
forthcoming medical innovations that involve genetic modification. 
I. INTRODUCTION 
The 2010 Nobel Prize in Physiology or Medicine was awarded to Robert G. 
Edwards "for the development of in vitro fertilization." 1 In awarding the prize, the Nobel 
Committee noted that Dr. Edwards' "achievements have made it possible to treat 
infertility, a medical condition afflicting a large proportion of humanity including more 
than 10 percent of all couples worldwide."2 Since the birth of the first child using in 
vitro fertilization (a form of assisted reproductive technology) in 19783 in the United 
Kingdom, various strides have been made in assisted reproductive technology. Yet while 
the United States has been a leader in many domains of technological innovation and 
regulation, the same characterization does not apply to the United States' place in 
assisted reproductive technology ("ART").4 Most recently, forms of ART involving 
genetic modifications have been developed in both the United Kingdom and the United 
States.5 A number of media and scientific publications have noted that the United States 
t Assistant Professor, William & Mary Law School; J.D., Columbia Law School; 
A.B., Harvard College. For helpful comments and suggestions, I would like to thank Aaron-Andrew Bruh!, 
Evan Criddle, Tara Grove, Lisa Ikemoto, Allison Orr Larsen, Sonia Suter, and participants at the 2019 
American Journal of Law and Medicine Symposium. 
1 Press Release, The Nobel Assembly at Karolinska Institutet, The Nobel Prize in Physiology or Medicine 
2010 (Oct. 4, 2010),, https://www.nobelprize.org/prizes/medicine/2010/press-release/ 
[https://perma.cc/CK2M-NNJE]. 
2 Id. 
3 See Genelle Weule, First IVF Baby's 40th Birthday: How a Tiny Girl Changed Science and the World, ABC 
NEWS (July 24, 2018), https://www.abc.net.au/news/science/2018-07-25/first-ivf-baby-louise-joy-brown­
tums-40/10017032 [perma.cc/BK2Y-XAAY]. 
4 For example, Professor Daniel Carpenter has observed that "the United States still houses the strongest of 
global pharmaceutical regulators" after being the first such regulator in the world. DANIEL P. CARPENTER, 
REPUTATION AND POWER: ORGANIZATIONAL IMAGE AND PHARMACEUTICAL REGULATION AT THE FDA 42 
(2010). 
5 See Myrisha S. Lewis, How Subterranean Regulation Hinders Innovation in Assisted Reproductive 
Technology, 39 CARDOZO L. REV. 1239, 1242-44, 1247-51 (2018) [hereinafter Subterranean Regulation]. 
While the first child to be born using mitochondrial transfer was purportedly born in Ukraine, because there 
is no system of regulation in Ukraine, that country is not a subject of the comparative analysis in this Article. 
See Susan Scutti, Controversial IVF Technique Produces a Baby Girl - and for Some, That's a Problem, CNN 
(Jan. 18, 2017), https://www.cnn.com/2017/01/18/health/ivf-three-parent-baby-girl-ukraine-bn/index.html 
[https://perma.cc/DV2J-4CKH]; see also infra Part III (discussing U.S. and U.K. innovation in assisted 
reproductive technology). 
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will lag behind the United Kingdom in ART development due to regulatory barriers that 
prevent the approval of a new form of ART, mitochondrial transfer, which combines in 
vitro fertilization with genetic modification in order to prevent the transmission of 
genetic disease.6 
Newer forms of ART, such as mitochondrial transfer and cytoplasmic transfer, 
another form of ART used in the late 1990s that also combined traditional ART with 
genetic modification (also referred to as "advanced assisted reproductive technologies"), 
raise interesting federalism issues: the U.S. Food and Drug Administration ("FDA") has 
asserted jurisdiction over these forms of ART, meanwhile state law governs the practice 
of medicine and family formation.7 This article will examine the regulation of 
mitochondrial transfer in the United States and the United Kingdom, as well as the 
regulation of an earlier, similar technique of ART, cytoplasmic transfer.8 Research on 
that technique in the United States has been suspended since at least 2001, when the 
FDA sent letters threatening legal action to physicians researching the technique.9 The 
FD A's assertion of jurisdiction over in vitro fertilization ("IVF") practice in 2001, which 
is usually the subject of state regulation, had a negative impact on research and clinical 
use of other IVF techniques, including mitochondrial transfer. 10 Also, by not addressing 
the safety and ethical issues related to cytoplasmic transfer in 2002, the United States 
6 Nina Bai, Three- Parent Babies: The Science of Replacing Mitochondrial DNA and What Remains Unknown, 
UCSF NEWS CENTER (Jan. 17, 2017), https://www.ucsf.edu/news/2017/0 l/405486/three-parent-babies­
science-replacing-mitochondrial-dna-and-what-remains-unknown [perma.cc/8NCV-UBUU]; Steve Connor, 
Three- Parent Baby Pioneer: "The Brits Will be Ahead of the World'", THE INDEPENDENT (Jan. 17, 2015) ('"At 
least the Brits get it. They will be ahead of the world. It's too bad it's taken so long. It could have been done 
15 years ago. I put my toe in the water and got shark bite, so I'm done with it. It's too bad because it cramps 
creativity, it inhibits medical progress."') (quoting Dr. Jamie Grifo, and American researcher whose work on 
"three-parent in vitro fertilization" was halted by the U.S. Food & Drug Admin.); Mitochondrial Donation 
Treatment, HUMAN FERTILISATION & EMBRYOLOGY AUTH., https://www.hfea.gov.uk/treatments/embryo­
testing-and-treatments-for-disease/mitochondrial-donation-treatment/ [https://perma.cc/2AR8-MQDE]. 
"Three-parent in vitro fertilization'' is the colloquial term for mitochondrial donation, which is also referred 
to as mitochondrial transfer, or mitochondrial donation therapy. See HUMAN FERTILISATION & EMBRYOLOGY 
AUTH., SCIENTIFIC REVIEW OF IBE SAFETY AND EFFICACY OF MEIBODS TO AVOID MITOCHONDRIAL 
DISEASE THROUGH ASSISTED CONCEPTION: 2016 UPDATE 42, 57 (2016), 
https://www.hfea.gov.uk/media/26l l /fourth_scientific_review_mitochondria_20l6.pdf. 
7 For more on federalism, see Nicholas Bagley, Federalism and the End ofObamacare, 127 YALE L.J. FORUM 
1, 2 (2017); Timothy Zick, Are the States Sovereign?, 83 WASH. U. L. Q. 229, 255, 292-94 (2005). For more 
on newer forms of ART, see Myrisha S. Lewis, Halted Innovation: The Expansion of Federal Jurisdiction 
Over Medicine and the Human Body, 2018 UTAH L. REV. 1073, l lOO (2018) [hereinafter Halted Innovation]; 
Subterranean Regulation, supra note 5, at 1241-45, 1248 ("A cell essentially contains three parts: cytoplasm, 
nucleus, and mitochondria. The nucleus, which is the center of the cell, is surrounded by cytoplasm. 
Mitochondria are located in the cytoplasm of the cell." (citations omitted)). Mitochondrial transfer and 
cytoplasmic transfer, two teclmiques of assisted reproductive technology, involve the modification of less than 
.0001 percent of DNA; however, the modification of DNA (even though it is not the "nuclear DNA" that 
dictates hair color and eye color for example), has led to opposition to the techniques. Mitochondrial transfer 
is currently being used to prevent the transmission of genetic disease whereas cytoplasmic transfer was used 
to improve fertility outcomes. Infra Part III.A 
8 Connor, supra note 6; see Don P. Wolf et al., Mitochondrial Replacement Therapy in Reproductive Medicine, 
21 TRENDS IN MOLECULAR MED. 68, 72 (2015) ("In 1998-1999, cytoplasmic transfer, or the augmentation of 
patient eggs with a small volume (1-5%) of donor cytoplasm was used by several IVF clinics in an effort to 
overcome repeated IVF failures in selected patients. The procedure essentially involved co-injection of donor 
cytoplasm with sperm, as an extension of [intracytoplasmic sperm injection]. Several pregnancies were 
established before the US FDA, for regulatory purposes, insisted that an investigational new drug application 
be filed before the success or failure of this approach could be determined."). 
9 See Subterranean Regulation, supra note 5, at 1259-62. 
10 See id. at 1256, 1259-62 (discussing the "chilling effects" of the FD A's method of regulation on advanced 
assisted reproductive technologies including cytoplasmic transfer and mitochondrial donation). 
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fell further behind in the race towards the clinical use of mitochondrial transfer as a 
number of safety and ethical issues overlap between cytoplasmic transfer and 
mitochondrial transfer.11 Instead, U.S.-based physicians and patients have been driven 
to reproductive tourism where they provide these techniques in countries with less 
restrictive regulation. 12 Thus, those opposed to the type of work involving mitochondrial 
transfer have succeeded in halting the use of the technique in the United States, whereas 
institutional structures in the United Kingdom have thoroughly considered the ethical 
and legal issues surrounding the use of the technique before ultimately approving it. 13 
This article applies a comparative analysis to ART innovation before 
concluding that the United States should undertake a public consultation related to ART 
innovation similar to the United Kingdom. The political science subfield of comparative 
politics has often focused on the European Union's purported "democratic deficit," 
which some have blamed for the U.K. 's vote to leave the E.U. 14 While there is no 
standard definition of the "democratic deficit," generally, when a national or 
supranational body suffers from a "democratic deficit," that body lacks public 
accountability, transparency, and public engagement. 15 As explained infra, the United 
Kingdom's approach to this technique was to eventually legalize it after an extensive 
public consultation, whereas the United States' approach has been to use administrative 
law to hinder the use of this technology, and a preceding but similar technology, 
cytoplasmic transfer, without having any public discourse on the social, ethical, and 
political considerations implicated by the technique. 16 
This article contributes to the health law, family law, innovation law, and 
administrative law literatures. In health law and family law, there is a significant (and 
11 Id. at 1271-79. 
12 See sources cited infra note 117 and accompanying text discussing the work of Dr. Jolm Zhang, a U.S.­
based physician, in Mexico; infra notes 195, 199 discussing reproductive and medical tourism. 
13 See infra Part III; see also Doctors Given Approval for UK's First 'Three- Person Babies', BBC NEWS (Feb. 
2, 2018), https://www.bbc.com/news/health-42918341 [https://perma.cc/U92N-LTEE]. 
14 See K.K. DuVivier, The United States as a Democratic Ideal? International Lessons in Referendum 
Democracy, 79 TEMP. L. REV. 821, 855 n. 245 (2006); R. Daniel Kelemen, Europe's Other Democratic 
Deficit: National Authoritarianism in Europe's Democratic Union, 52 Gov'T & OPPOSITION 211, 211 ("For 
years, many scholars of European integration have argued that the EU suffers from a democratic deficit, due 
to the lack of public engagement and political accountability at the EU level and the absence of a common 
public sphere or common demos characteristic of national democracies."); id. at 211 n.l; Stephen C. 
Sieberson, The Proposed European Union Constitution - Will it Eliminate the EU's Democratic Deficit?, 10 
COLUM. J. EUR. L. 173, 174 (2004); id. at 195 ('"Democratic deficit . . .  refers to the legitimacy problems of 
non-majoritarian institutions, i.e., institutions which by design are not directly accountable to the voters or to 
their elected representatives."' (citing Giandomenico Majone, Europe's 'Democratic Deficit': The Question 
of Standards, 4 EUR. L.J. 5, 15 (1998)). 
15 See Andreas Follesdal & Simon Hix, Why There is a Democratic Deficit in the EU: A Response to Maj one 
and Moravcsik, 44 J. COMMON MKT. STUD. 533,534 (2006) ("There is no single meaning of the 'democratic 
deficit'. Definitions are as varied as the nationality, intellectual positions and preferred solutions of the 
scholars or commentators who write on the subject. Making a similar observation in the mid-1990s, Joseph 
Weiler and his colleagues set out what they called a 'standard version' of the democratic deficit."); 534-36 
(providing five elements of a "standard version " of the democratic deficit: "First, and foremost, European 
integration has meant an increase in executive power and a decrease in national parliamentary control.. 
Second, and related to the first element, most analysts of the democratic deficit argue that the European 
Parliament is too weak. . . . Third, despite the growing power of the European Parliament, there are no 
'European' elections . . . .  Fourth, even if the European Parliament's power were increased and genuine 
European elections were able to be held, another problem is that the EU is simply 'too distant' from voters . 
. Fifth, European integration produces 'policy drift' from voters' ideal policy preferences."); Peter L. 
Lindseth, Democratic Legitimacy and the Administrative Character of Supranationalism: The Example of the 
European Community, 99 COLUM. L. REV. 628,657,684 (1999). 
16 See Subterranean Regulation, supra note 5, at 1241-45; infra Part III;. 
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often overlapping) literature addressing ART innovation and the consequences of using 
ART.17 The article simultaneously contributes to the health law and administrative law 
literatures by revealing how the operation of administrative law may be hindering 
innovation in medicine. 18 More specifically,, the article contributes a specific subset of 
the "health-care administrative law" literature surrounding ART and innovative 
therapies by using the concept of "democratic deficit," a political science concept, to 
illustrate a lack of transparency and public participation in the regulation of innovations 
in AR T.19 Moreover, from the perspective of innovation and technology governance, the 
divergent experiences of the United States and the United Kingdom on advanced 
assisted reproductive technologies indicates that, in the realm of advanced assisted 
reproductive technology, the general approach to risk where, "for example Europe tends 
to give greater prominence to precaution while the United States assigns a stronger role 
to liability" is reversed. 20 Due to the role of administrative institutions in the analysis, 
the article also implicates comparative administrative law and comparative health law.21 
17 See Michele Goodwin, Prosecuting the Womb, 76 GEO. WASH. L. REV. 1657, 1693 (2008); Alexander N. 
Hecht, The Wild Wild West: Inadequate Regulation of Assisted Reproductive Technology, 1 HOUS. J. HEALTH 
L. &POL'Y 227, 228 (2001); see also NAOMIR. CAHN, TEST TuBEFAMILIES: WHY THE FERTILITY MARKET 
NEEDS LEGAL REGULATION vii, 1-10 (2009); DEBORA L. SPAR, THE BABY BUSINESS: How MONEY, SCIENCE, 
AND POLITICS DRIVE THE COMMERCE OF CONCEPTION 5 (2006); Courtney M. Cahill, The Oedipus Hex: 
Regulating Family After Marriage Equality, 49 U.C. DAVIS L. REV. 183 (2015); Naomi R. Chan & Jennifer 
M. Collins, Eight is Enough, 103 NW. U. L. COLLOQUY 501, 507 (2009); Judith F. Daar, Regulating 
Reproductive Technologies: Panacea or Paper Tiger?, 34 HOUS. L. REV. 609, 615 (1997) ("[Assisted 
reproductive technology] is subject to little formal regulation"); Marsha Garrison, Regulating Reproduction, 
76 GEO. WASH. L. REV. 1623 (2008); Hank Greely, Cloning and Government Regulation, 53 HASTINGS L.J. 
1085, 1089-90 (2002); Kathryn V. Lorio, The Process of Regulating Assisted Reproductive Technologies: 
What We Can Learn from Our Neighbors- What Translates and What Does Not, 45 LOY. L. REV. 247, 247 
(1999); Kimberly M. Mutcherson, Blood and Water in a Post- Coital World, 49 FAM. L. Q. 117, 127 (2015); 
Lars Noah, Assisted Reproductive Technologies and the Pitfalls of Unregulated Biomedical Innovation, 55 
FLA. L. REV. 603, 614-15 (2003); Gaia Bernstein, Regulating Reproductive Technologies: Timing, 
Uncertainty, and Donor Anonymity, 90 B.U. L. REV. 1189, 1196-1205 (2010); June Carbone & Paige 
Gottheim, Markets, Subsidies, Regulation, and Trust: Building Ethical Understandings into the Market for 
Fertility Services, 9 J. GENDER RACE & JUST. 509, 511 (2006) ("The regulation offertility services involves 
the creation of norms about a new and rapidly growing technology.). 
18 See Timothy S. Jost, Health Law and Administrative Law: A Marriage Most Convenient, 49 ST. LOUIS U. 
L. J. 1, 14-16, 29 (2004); infra Part LB. 
19 See, e.g., Daniel A Farber & Anne J. O'Connell, The Lost World of Administrative Law, 92 TEX. L. REV. 
1137, 1137 (2014) (identifying administrative law's goals as "transparency, rule of law, and reasoned 
implementation of statutory mandates"); Emily Hammond & David L. Markell, Administrative Proxies for 
Judicial Review: Building Legitimacy from the Inside-Out, 37 HARV. ENVTL. L. REV. 313, 316 (2013) 
(identifying "administrative law values of participation, deliberation, and transparency, which guard against 
arbitrariness and foster accountability"); Jost, supra note 18, at 1 (referring to the concept of "health-care 
administrative law"); id. at 9-14; Michael A Livermore, Political Parties and Presidential Oversight, 67 ALA. 
L. REV. 45, 110 (2015); Robert Rohrschneider, The Democracy Deficit and Mass Support for an EU- Wide 
Government, 46 AM. J. OF POLI. SCI. 463, 463 (2002); Miriam Seifter, Second-Order Participation in 
Administrative Law, 63 UCLA L. REV. 1300, 1302 (2016) ("[P]ublic participation is a cornerstone of 
administrative law.") 
20 Gary Marchant, Resilience: A New Tool in the Risk Governance Toolbox for Emerging Technologies, 51 
U.C. DAVIS L. REV. 233, 245 (2017). 
21 See Francesca Biguami, From Expert Administration to Accountability Network: A New Paradigm for 
Comparative Administrative Law, 59 AM. J. COMP. L. 859, 860 (2011) ("Comparative administrative law .. 
seeks to uncover the similarities and differences that mark multiple legal systems."); Susan Rose-Ackerman, 
Comparative Administrative Law: Outlining a Field of Study, 28 WINDSOR Y.B. ACCESS JUST. 435, 436 
(2010). For more on comparative health law, see generally Diane Hoffmann, Comparative Health Law and 
Policy: What, If Anything, Can We Learn from Other Countries?, 37 J.L. MED. & ETHICS 790 (2009). 
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Ultimately, the lessons from this project may be useful for or extrapolated to other 
regimes.22 
The article proceeds as follows. In part II, the article provides background 
information on ART and the concept of the democratic deficit. In part III, the article 
provides an overview of the regulatory systems governing innovation in and the use of 
ART in the United States and the United Kingdom, with an emphasis on the two 
countries' disparate regulatory approaches to traditional and newer forms of ART 
involving genetic modification. Part IV uses the comparative and domestic legal 
analyses from part III to explore the implications of the United States' approach to ART 
regulation on innovation in the United States, including the existence of a democratic 
deficit in ART innovation and use in the United States. Part V prescribes a potential 
process of public consultation for the U.S., based on the U.K. 's five-strand consultation 
on mitochondrial transfer, before concluding. 
II. SCIENTIFIC AND CONCEPTUAL BACKGROUND 
This part provides background in the areas of political science and ART. 
Section A describes the broader concept of ART, with an emphasis on IVF before 
describing "advanced assisted reproductive technologies" which are forms of ART 
involving genetic modification that are distinct from gene editing, another innovation 
that has received significant media attention lately. 23 Section B offers an overview of 
the concept of "democratic deficit." 
A. ASSISTED REPRODUCTIVE TECHNOLOGY 
The term "ART" can have many definitions depending on the purposes for 
which the term is being used. ART is a broad field that "usually involves in vitro 
22 See Sandy Ong, Singapore Could Become the Second Country to Legalize Mitochondrial Replacement 
Therapy, SCIENCE ( Jun. 6, 2018), http://www.sciencemag.org/news/2018/06/singapore-could-become­
second-country-legalize-mitochondrial-replacement-therapy [https://perma.cc/BTY2-PMSX]; Scientists Say 
it's Time to Make '3- Parent Baby' Technology Legal in Canada, CBC RADIO (Mar. 26, 2018), 
https://www.cbc.ca/radio/quirks/march-24-2018-an-alien-looking-skeleton-three-parent-families-in-canada­
and-more- l .  4588650/scientists-say-it-s-time-to-make-3-parent-baby-technology-legal-in-canada-l .  4588671 
[https://perma.cc/ZN5R-SZ4C] (providing comment of Health Canada on possible legal changes to 
accommodate new forms of assisted reproductive technology, "Health Canada is the federal authority 
responsible for administering and enforcing the Assisted Human Reproduction (AHR) Act. The AHR Act 
prohibits a person from knowingly altering the genome of a cell of a human being or in vitro embryo such that 
the alteration is capable of being transmitted to descendants. Genome is defined in the AHR Act as the totality 
of the deoxyribonucleic acid (DNA) sequence of a particular cell. Since mitochondrial replacement therapy 
involves the introduction of mitochondrial DNA from a third party and since the introduced DNA is capable 
of being inherited by the resulting embryo, a person performing this procedure in Canada would be violating 
a provision of the AHR Act. . . .  After the current regulatory project is complete, the Department will consider 
the need to amend the Assisted Human Reproduction (AHR) Act to reflect advances in science that have taken 
place since the Act was first enacted in 2004. This will include revisiting the prohibition in the Act that 
currently makes it illegal in Canada for a person to conduct mitochondrial replacement therapy (MRT). Health 
Canada recognizes the promise that the application of this technology, and other technologies that create 
heritable changes to the genome, may hold. However, further consideration is required, including whether 
changes to the prohibitions would continue to reflect the values of Canadians, before such changes could be 
contemplated."). 
23 See Subterranean Regulation, supra note 5, at 1241. This Article focuses on forms of assisted reproductive 
technology involving genetic modification such as mitochondrial transfer and cytoplasmic transfer, although 
as will be explained in Parts III and IV, the lessons from this Article, which addresses medical techniques that 
are accompanied by ethical controversy, could eventually be relevant in similar studies of gene editing 
technologies. This Article focuses on assisted reproductive technology involving heritable genetic 
modifications, and while there are some aspects of it that are similar to gene editing (and many that are not), 
comparative aspects of the regulation of gene editing will be the focus of a subsequent Article. 
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fertilization," where "an egg is removed from [a] woman's ovary and fertilized with [a] 
man's sperm in a petri dish" in a laboratory setting. 24 "If fertilization occurs, the resulting 
embryo is" implanted into a woman's utems.25 In the United States, the Centers for 
Disease Control and Prevention ("CDC"), which is part of the U.S. Department of 
Health and Human Services ("HHS"), explains the term as 
" .. . includ[ing] all fertility treatments in which both eggs and embryos 
are handled. In general, ART procedures involve surgically removing 
eggs from a woman's ovaries, combining them with sperm in the 
laboratory, and returning them to the woman's body or donating them to 
another woman. They do NOT include treatments in which only sperm 
are handled (i.e., intrauterine-or artificial-insemination) or 
procedures in which a woman takes medicine only to stimulate egg 
production without the intention of having eggs retrieved."26 
The CDC's definition of ART draws on the only federal statute that is clearly applicable 
to ART, the 1992 Fertility Clinic Success Rate Act.27 Other operating divisions of the 
HHS use similar definitions, as do the National Academies of Science, Engineering, and 
Medicine, Society for Assisted Reproductive Technology, and American College of 
Obstetricians and Gynecologists. 28 In the United Kingdom, the Human Fertilisation and 
Embryology Authority, National Health Service, and the UK's National Institute for 
Health and Care Excellence use similar definitions of ART (also referred to as "assisted 
conception") and "fertility treatment," as the CDC.29 
24 Lori B. Andrews & Lisa Douglass, Alternative Reproduction, 65 S. CAL. L. REV. 623, 631 (1991); see 
Frequently Asked Questions: Gynecologic Problems, AM. COLLEGE OF OBSTETRICIANS & GYNECOLOGISTS 
(Oct. 2017), https://www .acog.org/Patients/F AQs/Treating-Infertility?IsMobileSet=false#assisted 
[https://perma.cc/V9ZY-R8XC]. For an overview of the mechanics of in vitro fertilization, see John A 
Robertson, Embryos, Families, and Procreative Liberty: The Legal Structure of the New Reproduction, 59 S. 
CAL. L. REV. 939, 944-52 (1986). 
25 Andrews & Douglass, supra note 24, at 631; see Lars Noah, Assisted Reproductive Technologies and the 
Pitfalls of Unregulated Biomedical Innovation, 55 FLA. L. REV. 603, 608 (2003) (characterizing in vitro 
fertilization as "represent[ing] the paradigmatic form of ART"). 
26 What is Assisted Reproductive Technology?, CTRS. FOR DISEASE CONTROL & PREVENTION (Feb. 7, 2017), 
https://www.cdc.gov/art/whatis.html [https://perma.cc/Q5B7-W25L]. 
27 Id.; see 42 U.S.C. §§ 201, 263a-l -a-7 (2012); Yaniv Heled, The Regulation of Genetic Aspects of Donated 
Reproductive Tissue-The Need for Federal Regulation, 11 COLUMBIA SCI. & TECH. L. REV. 243, 250-51 
(discussing the Fertility Clinic Success Rate Act of 1992); Jamie King, Predicting Probability: Regulating the 
Future of Preimplantation Genetic Screening, 2 YALE J. HEALTH LAW, POL'Y, & ETHICS 101, 153 (2008) 
(noting that "[o]verall, the CDC has very limited power over ART clinics. [The Fertility Clinic Success Rate 
Act] specifically states that the "Secretary [of the Department of Health and Human Services] may not 
establish any regulation, standard or requirement which has the effect of exercising supervision or control over 
the practice of medicine in ART programs."). 28See NAT'L RESEARCH COUNCIL, SCIENTIFIC AND MEDICAL ASPECTS OF HUMAN REPRODUCTNE CLONING 
61 (2002); Assisted Reproductive Technology, NAT'L CANCER INSTIT. DICTIONARY OF GENETICS TERMS, 
https://www.cancer.gov/pub lications/ dictionaries/ genetics-dictionary/ def/assisted-reproductive-technology 
[https://perma.cc/GA6B-9N3L] ("A term used to describe collectively a number of noncoital methods of 
conception that are used to treat infertility with donor or nondonor eggs and sperm including in vitro 
fertilization (IVF), gamete intrafallopian transfer (GIFT), and zygote intrafallopian transfer (ZIFT). Also 
called ART."); Assisted Reproductive Technologies, SOC'Y FOR ASSISTED REPRODUCTIVE TECH., 
https ://www.sart.org/topics/topics-index/ assisted-reproductive-technologies/ [https :/ /perma. cc/SFT2-V8 SC]. 
29 NAT'L HEALTH SERV., CLINICAL COMMISSIONING POLICY: ASSISTED CONCEPTION, REFERENCE, 2014, : N­
SC/037, at 5-7, 9, https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/20l4/ l l /n­
sc037.pdf ("Assisted reproduction [:] The collective name for treatments designed to lead to conception by 
means other than sexual intercourse. Assisted reproduction techniques include intrauterine insemination (IUI), 
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Two techniques of ART, cytoplasmic transfer and mitochondrial transfer, 
combine IVF with genetic modification by combining or substituting, respectively, the 
genetic material of the sperm and eggs that would usually be used in IVF, with the 
genetic material from the mitochondria or cytoplasm of a donor egg. 30 Mitochondrial 
transfer, or mitochondrial donation, is a form of ART that aims to prevent the 
transmission of mitochondrial disease from parent to child.31  There are two techniques 
that are encompassed by the term "mitochondrial transfer": pronuclear transfer ("PNT") 
and maternal spindle transfer ("MST").32 These two techniques are the most commonly 
analyzed in contemporary media coverage of mitochondrial transfer and reports related 
to approval of the techniques. 33 Cytoplasmic transfer is a form of ART that has received 
less media attention lately but was a "precursor" to mitochondrial transfer.34 
Cytoplasmic transfer involves IVF, where the egg of the intended mother would be 
"revitalized" by the cytoplasm of a donor egg, in a technique that improved fertility 
outcomes in the 1990s and early 2000s. 35 As will be detailed infra in Part II, both 
cytoplasmic transfer and mitochondrial transfer have been subject to FDA responses that 
have had "chilling effects" on research and clinical practice. 
Other than the Fertility Clinic Success Rate Act, professional organizations, 
such as the American College of Obstetricians and Gynecologists and Society for 
Assisted Reproductive Technology, play an important role in the regulation of 
in vitro fertilisation (IVF), intracytoplasmic sperm irtjection (ICSI) and donor insemination (DI). The term 
'assisted reproduction technology' (ART) is the term sometimes used to collectively describe these procedures 
and inte1Ventions."); Explore Fertility Treatments, HUMAN FERTILISATION & EMBRYOLOGY AUTH. (Nov. 9, 
2018), https://www.hfea.gov.uk/treatments/explore-all-treatments [https://perma.cc/KH8M-DN36] 
(describing intrauterine insemination (IUI), in vitro fertilization, Intracytoplasmic sperm injection (ICSI), 
fertility drugs, IVF options, surgical sperm extraction, surgeiy, and surrogacy); Fertility Problems: Assessment 
and Treatment, Clinical Guideline [CGJ56], NAT'L INST. FOR HEALTH & CARE EXCELLENCE (Feb. 2013), 
https://www.nice.org.uk/guidance/cgl56/ifp/chapter/assisted-reproduction [https://perma.cc/6CFD-4CYX] 
(" Assisted reproduction [:] Assisted reproduction is the name given to treatments that can help you get 
pregnant without you having sexual intercourse. There are a variety of treatments, and what is suitable for you 
will depend on your own circumstances. The options include: intrauterine insemination (IUI)[;] in vitro 
fertilisation (IVF)[;] IVF with intracytoplasmic sperm irtjection (ICSI)[;] the use of donor sperm (donor 
insemination) or eggs (egg donation) . . . .  Other methods of assisted reproduction called gamete intrafallopian 
transfer (GIFT) or zygote intrafallopian transfer (ZIFT) are not recommended. Certain forms of assisted 
reproduction (IUI, IVF, ICSI, donor insemination and egg donation) are regulated by law and their use is 
controlled by the Human Fertilisation and Embiyology Authority"); How We Regulate, HUMAN 
FERTILISATION & EMBRYOLOGY AUTH., https://www.hfea.gov.uk/about-us/how-we-regulate/ 
[https://perma.cc/TF4S-E8BZ]. 30 See Subterranean Regulation supra note 5, at 1248-49 ("A cell essentially contains three parts: cytoplasm, 
nucleus, and mitochondria. The nucleus, which is the center of the cell, is 
surrounded by cytoplasm. Mitochondria are located in the cytoplasm of the cell." (citations omitted)); see also 
Paula Amato et al., Three- Parent IVF: Gene Replacement for the Prevention of Inherited Mitochondrial 
Diseases, 101 FERTIL. STERIL. 31, 32-34 (2014). 31 For more explanation of how the various techniques of mitochondrial transfer operate, see AS. Reznichenko 
et al., Mitochondrial Transfer: Implications for Assisted Reproductive Technologies, 11 APPLIED & 
TRANSLATIONAL GENOMICS 40, 41-44 (2016); Tian Wang et a!., Polar Body Genome Transfer for Preventing 
the Transmission of Inherited Mitochondrial Diseases, 157 CELL 1591, 1591 (2014); Wolf et al., supra note 
8, at 69-71. 
32 See NUFFIELD COUNCIL ON BIOETHICS, NOVEL TECHNIQUES FOR THE PREVENTION OF MITOCHONDRIAL 
DNA DISORDERS: AN ETHICAL REVIEW vii, 36 (2014) ("The main difference between [maternal spindle 
transfer and pronuclear transfer] is that MST uses two unfertilized eggs to reconstruct an egg with healthy 
mitochondria that can be fertilized; in PNT, two early embiyos (zygotes) are used to reconstruct an embiyo 
with healthy mitochondria."); Mitochondrial Donation Treatment, supra note 6. 33 See NUFFIELD COUNCIL ON BIOETHICS, supra note 32, at 34. 
34 Subterranean Regulation, supra note 5, at 1248-50. 3s Id. 
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reproductive technology by serving as "self-regulatory" or "peer regulatory" 
organizations for physicians involved in the practice of ART.36 ART is highly regulated 
in the United Kingdom, as detailed in part III.A.I, but is minimally regulated in the 
United States, with the exception of forms of ART involving genetic modifications 
(referred to herein as "advanced assisted reproductive technologies"), which are highly 
regulated, as detailed in part III.B .1. 
In 2005, the UK's Human Fertilisation and Embryology Authority granted a 
license to researchers at Newcastle University to conduct mitochondrial research.37 In 
April 2010, a group of scientists at Newcastle University published a paper in the journal 
Nature, providing "proof of concept" of pronuclear transfer.38 In 2009, researchers at 
Oregon Health and Science University announced that they had successfully used 
maternal spindle transfer in rhesus macaques. 39 However, as is detailed in part III of the 
article, because the Oregon Health and Science University researchers were located in 
the United States, their work has been stymied by the machinations of the administrative 
state and Congressional funding restrictions. As will be emphasized in part IV of the 
article, there is a lack of public participation and transparency in those machinations of 
the administrative state, even though there are indications that those machinations 
involve the use of political or social considerations by FDA employees, without a 
statutory basis. 40 
B.  DEMOCRATIC DEFICIT 
The term "democratic deficit" was first used in 1977 and has since occupied a 
significant space in the political science literature. 41 Although there is no standard 
definition of "democratic deficit," the concept of the "democratic deficit" highlights a 
failure to achieve many of the goals of the American democratic state such as legitimacy, 36 See Robertson, supra note 24, at 1035-36 ("With adequate peer involvement, more explicit legal controls, 
such as the national licensing authority suggested in the Warnock Report, need not take root in American 
soil."); Jennifer L. Rosato, The Children of Art (Assisted Reproductive Technology): Should the Law Protect 
Them from Harm?, 2004 UTAH L. REV. 57, 66 (2004) ("The American Society for Reproductive Medicine 
(' ASRM') is the primary professional organization that oversees the field of reproductive medicine, and the 
Society of Assisted Reproductive Technology ('SART'), an affiliated organization, specifically covers IVF 
programs, in addition to other types of ART programs."(citations omitted)). The Institute of Medicine's 
recommendation on the eventual use of mitochondrial transfer in the United States were directed at both the 
FDA and "professional societies." See THE NAT'L ACADS. OF SCI., ENG'G. & MED., MITOCHONDRIAL 
REPLACEMENT TECHNIQUES: ETHICAL, SOCIAL, AND POLICY CONSIDERATIONS 7, 71, 99 (2016) ("The 
committee does not suggest an absolute limit on any eventual applicability of MR T to other conditions or 
diseases, but rather believes FDA and relevant professional societies need to take a cautious approach, with 
deliberate attention to ethical, social, and policy issues, in considering any uses of MRT beyond the primary 
indication of preventing transmission of serious mtDNA disease." (emphasis added)). 37 See NUFFIELD COUNCIL ON BIOETHICS, supra note 32, at 34. 38 See id. 39 See id. at 36; see also Sabrina Tavernies, His Fertility Advance Draws Ire, N.Y. TIMES (Mar. 18, 2014). 
40 See, e. g., Nina Mendelson, Disclosing "Political" Oversight of Agency Decision Making, 108 MICH L. REV. 
1127, 1130-31 (2010); Subterranean Regulation, supra note 5, at 1271-74. 41 See Sanford Levinson, How the United States Constitution Contributes to the Democratic Deficit in 
America, 55 DRAKE L. REV. 859, 860 (2007); Martin Nettesheim, Developing a Theory of Democracy for the 
European Union, 23 BERK.ELY J. INT'L L. 358, 358-59 n. l (2005); see also Daniel T. Deacon, Administrative 
Forbearance, 125 YALE L.J. 1548, 1589 (2016) ("One persistent criticism of the administrative state, and 
particularly of broad delegations, is that policy is frequently formulated through allegedly less transparent 
means. Less visible policymaking may lead to less accountable government." (citations omitted)). 
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transparency, and an "equilibrium" between democracy and effectiveness. 42 I use the 
term "democratic deficit" in this article to highlight the non-existence of those goals in 
the regulation of ART at the federal level, which occurs through the use of administrative 
law tools that do not involve notice-and-comment mlemaking or public participation. 
While not all political scientists ascribe to the concept of "democratic deficit" 
in the European Union, many analyses of the European Union and the United States 
have examined political and legal challenges through the lens of the democratic deficit. 43 
The term "democratic deficit[]" " . . .  first arose in debates about the legitimacy of the 
European Union ("EU"), and has continued to surface in debates about the legitimacy 
of the European Union and the analysis of actors in the European Union."44 Most 
recently, the Brexit vote has been analyzed as a response to the "democratic deficit" in 
the European Union.45 
As a matter of brief historical context, the European Union is characterized as 
suffering from a "democratic deficit" due to its institutional structures: the Ministers of 
the Council of the European Union are " . . .  a collectivity of nonelected civil servants" 
with the authority to pass binding, enforceable legislation, without the approval of the 
European Parliament, a legislative body that has been characterized as "weak."46 
42 See Jan Rovny, Approaches to the Democratic Deficit in the European Union, 19 PERSPECTNES: REV. OF 
CENTRAL EUR. AFFAIRS 109, l l0, 113 (2003); see also sources cited supra note 19 and accompanying text 
(identifying the goals of the American administrative state). 
43 See PIPPA NORRIS, DEMOCRATIC DEFICIT: CRITICAL CITIZENS REVISITED 3, 5 (20 l l )  ("The gap between 
aspirations and satisfaction is captured here by the concept of democratic deficits. The notion first arose in 
debates about the legitimacy of the European Union (EU). The core decision-making institutions in the EU 
have been regarded by some commentators as falling well short of the standards of democratic accountability 
and transparency that exist at the national level within each of the member states."); Levinson, supra note 41, 
at 861-62 ("There is in fact an interesting debate going on about the extent of the democratic deficit in 
Europe"); id. at 862-64 (discussing the democratic deficit in the context of election law and American federal 
and state constitutional law); id. at 862 n.4; Ernest A. Young, Protecting Member State Autonomy in the 
European Union: Some Cautionary Tales from American Federalism, 77 N.Y.U. L. REV. 1612, 1639 (2002) 
[hereinafter Protecting Member State Autonomy]; Maimon Schwarzschild, Complicated- But Not Too 
Complicated: The Sunset of E. U. Law in the UK. After Brexit, 39 CARDOZOL. REV. 905, 905 n.2 (2018); see 
also James Allan, Democracy, Liberalism, and Brexit, 39 CARDOZO L. REV. 879, 887-94 (2018) (discussing 
"democratic deficiencies" in the context of the European Union); Ernest A. Young, What Can Europe Tell Us 
About the Future of American Federalism?, 49 ARIZ. ST. L.J. l l09, 1136 (2017) [hereinafter Future of 
American Federalism]; Peter Millar, What's all this about the EU's 'Democratic Deficit'?, THE GUARDIAN 
(May 20, 2013 ), https://www.theguardian.com/commentisfree/2013/may /20/eu-democratic-deficit. 
[https://perma.cc/QXF7-PVXF]. 
44 See NORRIS, supra note 43, at 5; see also Andrew Moravcsik, Is There a 'Democratic Deficit' in World 
Politics? A Framework for Analysis, 39 Gov'T AND OPPOSITION 336, 337 (2004) (noting that the European 
Union "is widely considered to suffer from a 'democratic deficit', the redressing of which was the primary 
purpose for calling the ongoing constitutional convention and negotiation."). For more on the democratic 
deficit in the European Union, see J.H.H. Weiler, The Transformation of Europe, 100 YALE L.J. 2403, 2430, 
2466-7, 2469 (199l i  
45 See HAROLD D. CLARKE ET AL., BREXIT 72, l l4 (2017); Matthew Goodwin et al., For and Against Brexit: 
A Survey Experiment of the Impact of Campaign Effects on Public Attitudes toward EU Membership, BRITISH 
JOURNAL OF POLITICAL SCIENCE, at 1, 5 (2018); Samuel Issacharoff, Democracy's Deficits, 85 U. CHI. L. REV. 
485, 493-94 (2018) ("In this sense, the desperate gambit of Prime Minister David Cameron [in using the 
referendum on the UK's membership in the EU] . . .  well follows the pattern in the European Union of seeking 
to alter its perceived democratic deficit through greater use of referenda and other tools of direct democracy." 
(citations omitted)); Timothy G. Ash, As an English European, This is the Biggest Defeat of my Political Life, 
THE GUARDIAN (Jun. 24, 2016) (discussing "Euroskepticism"). 
46 Weiler, supra note 44, at 2465-68 (1991); see Overview, COUNCIL OF THE EUROPEAN UNION (Feb. 19, 
2019), https:/ /europa.eu/european-union/about-eu/institutions-bodies/council-eu _ en [https:/ /perma.cc/34 AT­
RF89]. While there are significant literatures in political science, comparative law, and administrative law that 
analyze the European Union, this Article only analyzes the European Union in order to illustrate the concept 
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Through structures that lack accountability, transparency, and legitimacy, such as the 
Council of the European Union, which 
exercise[s legislative power] 'behind closed doors' . . .  'and, at a lower level, by 
numerous committees of national experts, who are faceless and 
unaccountable,' [through] a process [which is] 'hardly consistent with the rules 
of democracy, even in the eyes of those who understand that in the formation 
of legislative proposals there is limited scope for transparency.' 47 
While the "democratic deficit" is a political science term that is generally 
applied to analyses of the European Union, it is relevant to legal analysis, especially as 
it relates to U.S. administrative law.48 In the legal literature, the term has been used to 
explore broader concerns in U.S. law, often from a comparative perspective in which 
scholars explore various issues related to the Constitution of the United States and state 
constitutions. 49 A lack of these democratic features leads to a democratic deficit similar 
to the one that scholars attribute to the European Union's method of governance through 
structures like the Council of the European Union.5° Further, methods of avoiding 
democratic deficit include increasing the representation of the public in the political 
system, which the American administrative state aims to do through methods of public 
participation like notice-and-comment mlemaking.51 Nonetheless, many aspects of 
federal administrative decision-making related to advanced assisted reproductive 
technologies do not include public participation, as will be emphasized in part III.52 
This article uses the political science concept of the "democratic deficit" to 
address the lack of American public discourse on the subjects of ART and more recently, 
advanced assisted reproductive technologies which involve genetic modifications in 
combination ART. While America's "democratic deficit" in the realm of ART does not 
have the same political consequences as the E.U. 's democratic deficit, there is no 
supranational body that can impose binding legislation on the American federal 
government without its approval, a democratic deficit still exists within the 
administrative state. Even though the appointment of the FDA Commissioner involves 
of the democratic deficit, which the Article then uses to examine the regulation of assisted reproductive 
technology in the United States and United Kingdom. 
47 Rovny, supra note 42, at l l0, 113; Sieberson, supra note 14, at 195. 
48 See Curtis A. Bradley, International Delegations, the Structural Constitution, and Non- Self-Execution, 55 
STAN. L. REV. 1557, 1558 n.3 (2003); Levinson, supra note 41, at 860 ("The term 'democratic deficit' has 
become a staple in contemporary political analysis."). 
49 See Future of American Federalism, supra note 43, at l l l2 ("Finally, the Brexit vote and the parallel rise 
of Euro skeptic movements in France and other Member States reflects profound popular concerns about the 
legitimacy of governance at the center. Although the United States has not generally been thought to suffer 
from the same sort of "democratic deficit " that haunts European discourse, we are experiencing profound 
frustration with gridlocked and nonresponsive government in Washington, reflected in the precipitous decline 
in public trust in national governing institutions. We are unlikely to see a 'Texit' (or perhaps more likely, a 
'Utexit' or 'West Virgexit') but it is nonetheless time to ask how the eroding legitimacy of national 
government may affect American federalism."(citations omitted)); Dragoljub Popovic, Prevailing of Judicial 
Activism Over Self-Restraint in the Jurisprudence of the European Court of Human Rights, 42 CREIGHTON L. 
REV. 361, 364 (2009) (discussing the democratic deficit in the context of unelected judges in the American 
judiciary). 
50 See sources cited supra note 43 (discussing the democratic deficit in the European Union with an emphasis 
on the Council of the European Union). 
51 Rovny, supra note 42, at l l2; see Kristin Hickman, Unpacking the Force of Law, 66 VANDERBILT L. REV. 
465, 520 (2013). 
52 See infra Part IILB. l. 
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both the Executive and Legislative Branches, which are both democratically accountable 
to the public, the democratic deficit where " . . .  a collectivity of nonelected civil servants" 
can incorporate social and political views into administrative agency decisions that are 
not subject to public input still has significant legal and practical consequences in the 
realms of access to ART due to the binding nature of many administrative agency 
decisions as will be highlighted in part III.53 Examining the FDA regulation of ART 
through the lens of the democratic deficit highlights how, in the context of FDA 
regulation of ART, the administrative state has operated to hinder the use of advanced 
assisted reproductive technologies. 54 
III. REGULATORY BACKGROUND 
This article uses a comparative legal (and political) analysis to explore the 
differences in the regulation of forms of ART involving genetic modification in the 
United States and the United Kingdom.55 The selected case studies are countries that 
have the technology to implement widespread use of mitochondrial transfer, but have 
diverged in terms of the clinical use and governance of the technology. 56 Not only are 
the United States and the United Kingdom two countries where the most scientific 
progress in mitochondrial transfer has occurred, the countries' govermnents share some 
historical and democratic commonalities.57 
53 Weiler, supra note 44, at 2465-68; see James T. O'Reilly, Losing Deference in the FDA 's Second Century: 
Judicial Review, Politics, and a Diminished Legacy of Expertise, 93 CORNELL L.REV. 939, 959-60 (2008) 
(describing the appointment processes for the Secretary of Health and Human Services (appointed by the 
President to his Cabinet) and the FDA Commissioner and other political appointees at the FDA (who are 
appointed by the President and confirmed by the Senate). 
54 For more on the "democratic deficit " in the context of the United Kingdom and the United States, see Future 
of American Federalism, supra note 43, at 1112. 
55 See Kathryn V. Lorio, The Process of Regulating Assisted Reproductive Technologies: What We Can Learn 
from Our Neighbors - What Translates and What Does Not, 45 LOY. L. REV. 247, 248-49 (1999) ("Although 
no one system, or any combination of systems, may be ideal for the United States to emulate, both 
understanding and insight may be gained from a comparative analysis."). 
56 While media reports have noted that scientists in China is making headway in the field of mitochondrial 
transfer, this Article does not focus on the experience of China as it would be difficult to draw lessons from 
the Chinese experience since the country is known for having a lack of regulation in the area of scientific 
research. Nevertheless, China's Academy of Sciences has been involved in multiple international germline 
editing summits. This Article does not explore the issue of whether mitochondrial transfer is "germline 
editing." For more on the definition of the germline, see Subterranean Regulation, supra note 5, at 1249-50, 
1276-78 (2018). For more on CRISPR-Cas9 gene editing in China, see Dennis Normile, CRJSPR Bombshell: 
Chinese Researcher Claims to Have Created Gene- Edited Twins, SCIENCE (Nov. 26, 2018), 
https ://www.sciencemag.org/news/20 18/ l l /  crispr-bomb shell-chinese-researcher-claims-have-created-gene­
edited-twins [https://perma.cc/8RLP-GACW]; Sarah Zhang, Chinese Scientists are Outraged by Reports of 
Gene- Edited Babies, Science, THE ATLANTIC (Nov. 27, 2018), 
https://www.theatlantic.com/science/archive/2018/l l /china-crispr-babies/576784/ [https:/ /perma.cc/R T2J-
62TJ] ("China has spent billions turning itself into a scientific powerhouse, but it still struggles with the 
perception that its scientists do not take ethics seriously. In 2015, when Chinese scientists raced ahead to use 
CRISPR to edit genes in human embryos, an international outcry ensued."). 
57 There are of course many similarities and differences between the United States and the United Kingdom, 
which have been (and continue to be) studied by scholars of comparative law, institutional design, and 
federalism. This Article only focuses on these similarities and differences as pertinent to the regulation of 
assisted reproductive technology by the United States and United Kingdom. For background, see Steven G. 
Calabresi, Does Institutional Design Make A Difference?, 109 NW. U. L. REV. 577, 578 (2015) ( characterizing 
the United Kingdom as an "otherwise stable western constitutional democrac[y ]"); but see id. at 582-83 ("In 
important respects, the U.S. federal government is far more powerful than the federal governments of the 
European Union, Argentina, Brazil, Germany, India, Mexico, Canada, Australia, South Africa, and, since 
devolution, the United Kingdom."); see also Martin Laffin & Alys Thomas, The United Kingdom: Federalism 
in Denial?, 29 PUBLIUS 89, 90-92, 106 (1999); Peter H. Schuck, Federalism, 38 CASE W. RES. J. INT'L L. 5, 
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For the purposes of comparing the regulation of ART in the United States and 
the United Kingdom, it is useful to note that lawmaking in the United Kingdom is also 
very similar to that in the United States, although some of the terminology differs.58 Just 
like in the United States, proposed legislation in the United Kingdom is called a "bill" 
and final legislation in the United Kingdom is an "Act."59 A statutory instrument is a 
"type of delegated legislation,"60 which is similar to a regulation in the United States 
where statutory instruments provide clarity on the meaning of various statutory terms.61  
Statutory instruments are normally drafted by the legal office of the relevant government 
department, which is why the draft regulations related to mitochondrial transfer were 
created by the UK Department of Health.62 Thus, in the realm of administrative law, the 
draft regulations permitting mitochondrial transfer became a "statutory instrument" after 
they were approved by Parliament.63 In the United States, relevant regulations related to 
mitochondrial transfer and other forms of ART are drafted by the FDA without any sort 
of legislative approval. 64 This part provides background on the legal responses to various 
innovations in ART in the United Kingdom and the United States. 
5-6 (2006); See also Erin Ryan, Secession and Federalism in the United States: Tools for Managing Regional 
Conflict in A Pluralist Society, 96 OR. L. REV. 123, 164 (2017) ()(discussing the United States' "symmetrical 
federalism" and the United Kingdom's "asymmetrical federalism"); 
58 As noted in the preceding footnote, there are of course many differences between lawmaking in the United 
States and United Kingdom; however, this paragraph (and the Article as a whole) focuses on detailing the 
aspects of lawmaking in the United States and the United Kingdom that are critical to understanding the 
regulation of assisted reproductive technology in both countries. Proposed legislation in the United Kingdom 
is called a "bill", and an Act is the term applied to a bill that has obtained a majority vote in both the House of 
Commons and House of Lords and "formal[] agree[ ment] by the reigning monarch (known as Royal Assent)." 
See Bills and Legislation, U.K. PARLIAMENT, http://www.parliament.uk/business/bills-and-legislation/ 
[https://perma.cc/A4HJ-72VJ]; House of Commons, U.K. PARLIAMENT, 
http://www.parliament.uk/business/commons/ [https://perma.cc/HW6A-JUS9] ("[t]he UK public elects 650 
Members of Parliament (MPs) to represent their interests and concerns in the House of Commons."); Members 
and Their Roles, U.K. PARLIAMENT, http://www.parliament.uk/business/lords/whos-in-the-house-of­
lords/members-and-their-roles/ [https://perma.cc/UHS8-47VP] ("Members of the House of Lords are 
appointed by the Queen on the advice of the Prime Minister"); see also Stephen Gardbaum, Political Parties, 
Voting Systems, and the Separation of Powers, 65 AM. J. COMP. L. 229, 230 (2017) ("When the same party 
wins both the White House and Congress, the United States has 'unified' government resembling 
parliamentary systems, notwithstanding the formal separation of the two branches. Only during periods of 
'divided' government, where different parties control the two branches, does the Framers' conception of 
institutional checks and balances--of ambition checking ambition--come close to reflecting the reality of 
American politics."). 
59 See sources cited supra note 58 and accompanying text. 
60 What is Secondary Legislation?, U.K. PARLIAMENT, http://www.parliament.uk/about/how/laws/delegated/ 
[https://perma.cc/MS69-VFP2]. 
61 Because Acts of Parliament are often broad, "[statutory instruments] are used to provide the necessary detail 
that would be too complex to include in the Act itself." HOUSE OF COMMONS INFORMATION OFFICE, 
STATUTORY INSTRUMENTS 2 (2008), https://www.parliament.uk/documents/commons-information­
office/107 .pdf. 
62 What is Secondary Legislation?, supra note 60; see Commons Debate Statutory Instrument on 
Mitochondrial Donation, U.K. PARLIAMENT (Feb. 3, 2015), 
http://www.parliament.uk/business/news/2015/febmary/commons-debate-statutory-instmment-on­
mitochondrial-donation/ [https://perma.cc/53QC-RXS5]; see Draft Regulations on 'Three Parent' IVF 
Published, NAT'L HEALTH SERV. (Feb. 28, 2014), http://www.nhs.uk/news/20l4/02Febmary/Pages/Draft­
regulations-on-three-parent-IVF-published.aspx [https://perma.cc/3DMS-A78E]. 
63 See Commons Debate Statutory Instrument on Mitochondrial Donation, supra note 62; The Human 
Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015, 2015 No. 572, THE NAT'L 
ARCHIVES (Mar. 4, 2015), http://www.legislation.gov.uk/ukdsi/2015/9780111125816/contents 
[https://perma.cc/GS5L-HUYD]. 
64 See PETER B. HUTT ET AL., FOOD AND DRUG LAW: CASES AND MATERIALS 1154 (4th ed. 2014). 
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The United Kingdom is a prominent country in terms of ART innovation. The 
work of Robert Edwards and Patrick Steptoe led to the birth of the world's first baby as 
a result of IVF, Louise Brown, in the United Kingdom in 1978.65 In July 1982, the 
"Committee of Inquiry into Human Fertilisation and Embryology" was created. 66 The 
committee's report, "the Warnock Report,"67 made 64 recommendations,68 including 
that IVF continue to be available through the National Health Service,69 that children 
conceived through IVF have the right to basic donor information including the donor's 
genetic health,"70 that written consent from couples using IVF be obtained,71 that semen 
donors not have parental rights, 72 and that various constraints apply to research involving 
human embryos. 73 These recommendations eventually led to the creation of the UK's 
Human Fertilisation & Embryology Authority and were incorporated into the United 
Kingdom's regulatory framework governing the use of ART and research related to 
innovation in ART.74 
1. The United Kingdom's Regulatory Framework Governing Assisted 
Reproductive Technology Use and Innovation 
65 The Nobel Assembly at Karolinska Institutet, supra note I. 
66 DEP 'T OF HEAL TH & Soc. SEC., REPORT OF THE COMMITTEE OF INQUIRY INTO HUMAN FERTILISATION AND 
EMBRYOLOGY (1984), https://www.hfea.gov.nk/media/2608/warnock-report-of-the-committee-of-inqniry­
into-human-fertilisation-and-embryology-1984.pdf [hereinafter WARNOCK REPORT]. 
67 See WARNOCK REPORT, supra note 66. For a chapter-by-chapter summary of the Warnock Report, see 
Jonathon J. LaTourelle, The Report of the Committee of Inquiry into Human Fertilisation and Embryology 
(1984), by Mary Warnock and the Committee of Inquiry into Human Fertilisation and Embryology, EMBRYO 
PROJECT ENCYCLOPEDIA (Oct. 2, 2014), https://embryo.asu.edu/pages/report-committee-inqniry-human­
fertilisation-and-embryology-1984-mary-warnock-and-committee [https://perma.cc/BV6K-V7BN]. ). 
68 WARNOCK REPORT, supra note 66, at 80-86 (providing a "List of Recommendations" related to the clinical 
use of assisted reproductive technology and research on embryos). 
69 Id. at 32. In the United Kingdom, health care is provided by the National Health Service, which was created 
in 1948. See Robert H. Blank, The United Kingdom: Regulation Through a National Licensing Authority, in 
COMPARATIVE BIOMEDICAL POLICY: GoVERNING ASSISTED REPRODUCTIVE TECHNOLOGIES 121 (2004). The 
National Health Service provides free health care for UK residents. See About the NHS, NAT'L HEAL TH SERV., 
(Apr. 13, 2016), http://www.nhs.nk/NHSEngland/thenhs/about/Pages/overview.aspx [https://perma.cc/S3FB­
LD8E]. 
70 WARNOCK REPORT, supra note 66, at 24-25. 
71 Id. at 25. 
n Id. 
73 See Mary Warnock, The Warnock Report, 291 BRIT. MED. J. 187, 187-89 (1985) (summarizing the Warnock 
Report). 
74 Donna M. Gitter, Am I My Brother's Keeper? The Use of Pre implantation Genetic Diagnosis to Create A 
Donor of Transplantable Stem Cells for an Older Sibling Suffering from a Genetic Disorder, 13 GEO. MASON 
L. REV. 975, 987 (2006); Margaret F. Riley & Richard A. Merrill, Regulating Reproductive Genetics: A 
Review of American Bioethics Commissions and Comparison to the British Human Fertilisation and 
Embyology Authority, 6 COLUM. SCI. & TECH. L. REV. I, 5 (2005). While an analysis of the United Kingdom's 
institutions may have required an analysis of European Union institutions and law, the United Kingdom, which 
has been categorized as "experienc[ing] a rising tide of mistrust about government institutions," voted in 2016 
to exit the European Union. See NORRIS, supra note 43, at 58. As such, the analysis of the U.K.'s regulatory 
structure infra largely neglects the European Union's regulatory process as, as of the time that this Article is 
being written, the U.K. is in the process of exiting the European Union. For more on "Brexit," see sources 
cited supra note 45 and accompanying text. 
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The U.K. has a robust system for regulating ART,75 which has been described 
as " . . .  perhaps the most well-developed."76 Unlike in the United States, where traditional 
ART is generally described as "minimally regulated" or "unregulated," all ART in the 
United Kingdom is highly regulated.77 In contrast to the lack of regulation in the United 
States ( or unexpected subterranean regulation by the FD A), the United Kingdom created 
a regulatory agency, the Human Fertilisation & Embryology Authority ("HFEA"), 
which regulates a number of matters related to ART.78 
The HFEA was authorized by the Human Fertility and Embryology Act of 
199079 and "set up in 1991."80 It "is the UK's independent regulator of treatment using 
eggs and sperm, and of treatment and research involving human embryos."81 The HFEA 
describes its goals as 
ensur[ing] that everyone who steps into a fertility clinic, and everyone born as 
a result of treatment, receives high quality care. We do this by licensing, 
monitoring and inspecting fertility clinics . . .  and providing free, clear and 
impartial information about fertility treatment, clinics and egg, sperm and 
embryo donation. We also collect data about fertility treatments. 82 
These goals stem from the agency's enabling statute (in American parlance) as the 1990 
Act (as amended) "gives the HFEA a number of statutory functions," including the 
licensing of fertility clinics and research centers, the maintenance of a register of adverse 
reactions and events and " . . .  regulat[ing] the storage of gametes and embryos . . .  "83 The 
1990 version of the Human Fertilisation and Embryology Act is generally referred to as 
"the 1990 Act (as amended)" ; it was subsequently amended in 2008.84 The agency also 
promulgates requirements related to the selection of donors of reproductive tissue. 85 
Further, the HFEA also publishes a Code of Practice which it incorporates into its 
75 Kerry L. Macintosh, Teaching About the Biological Clock: Age- Related Fertility Decline and Sex 
Education, 22 UCLA WOMEN'S L.J. 1, 26 (2015) (citing ROBERT EDWARDS & PAlRICK SlEPTOE, A MATIER 
OF LIFE: THE STORY OF A MEDICAL BREAKTHROUGH 11-15 (1980)). 
76 Steve P. Calandrillo & Chryssa V. Deliganis, In Vitro Fertilization and the Law: How Legal and Regulatory 
Neglect Compromised A Medical Breakthrough, 57 ARIZ. L. REV. 311, 333 (2015) 
77 See Calandrillo & Deliganis, supra note 76, at 333; Subterranean Regulation, supra note 5, at 1240 
("Commentators have described the regulatory environment surrounding assisted reproductive technology 
[in the United States] as 'limited,' 'minimally regulated,' and even 'the Wild Wild West.' [The article] reveals, 
however, that one important subset of assisted reproductive technology, the subset that contains forms of 
assisted reproductive technology that combine in vitro fertilization with the modification of small amounts of 
DNA . . .  is an exception to this general rule." (citations omitted)). 78 About Us, HUMAN FERTILISATION & EMBRYOLOGY AUTH., https://www.hfea.gov.uk/about-us/ 
[https://perma.cc/B9D2-A36D]. 
79 Hnman Fertilisation and Embryology Act, 1990, c. 37, § 5 (Eng.). 80 Human Fertilisation and Embryology Authority Access to Anonymised Data, HUMAN FERTILISATION & 
EMBRYOLOGY AUTH. (Nov. 23 2011), https://data.gov.uk/dataset/l bdda00f-d661-4901-bf4c-
6 3 9000 11 cb0d/human -fertilisation-and-embryo lo gy-authority-access-to-anonymised-data 
[https://perma.cc/U2HR-C5B2]. 
81 About Us, supra note 78. 82 Id. 83 See HUMAN FERTILISATION & EMBRYOLOGY AUTH., ANNUAL REPORT AND ACCOUNTS 2012/13 1, 8-9 
(2013), http://www.hfea.gov.uk/docs/HFEA_Annual_Report_and_Accounts_20l2 - l3.PDF [hereinafter 2013 
ANNUAL REPORT]; see Human Fertilisation and Embryology Act, 1990, c. 37, §§ 5-10 (Eng.); Calandrillo & 
Deliganis, supra note 77, at 333; About Us, supra note 78. 84 See 2013 ANNUAL REPORT, supra note 83, at 8. The "Human Fertilisation and Embryology Act 2008" is 
generally referred to as "the 2008 Act." 
85 See Heled, supra note 27, at 284-85. 
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regulation of ART, in addition to incorporating the guidelines of various physician 
societies, including the " . . .  British Andrology Society and the British Fertility 
Society."86 The Code of Practice is intended to aid with compliance with the 1990 Act 
and contains a number of mandatory requirements, such as those related to counseling, 
informed consent and parenthood, that apply to HFEA-licensed activities.87 
In 2013, the United Kingdom considered streamlining its healthcare-related 
bureaucracy in order to reduce administrative costs incurred by its National Health 
Service. 88 One of the options considered was the possibility of transferring the functions 
of the HFEA and Human Tissue Authority to the Commission on Quality Control and 
the Health Research Authority. 89 At the same time, the HFEA and its decisions have 
been criticized on a number of grounds, including those based on policy, the speed of 
using certain assisted reproductive technologies in humans, the use of ART, and the 
perspectives underlying the agency's decisions.90 In keeping with the general tendency 
in the United Kingdom to conduct public consultations when undertaking policy or legal 
changes, the UK conducted a public consultation on the continued existence of the 
HFEA.91 In January 2013, "the Department of Health announced that the HFEA would 86 Id. at 285; HUMAN FERTILISATION & EMBRYOLOGY AUTH., CODE OF PRACTICE 11 (9th ed. 2019), 
https://www.hfea.gov.uk/media/2793/20l9-0l -03-code-of-practice-9th-edition-v2.pdf ("One of the ways we 
help licensed centres comply with the Act is by publishing the Code of Practice. This is because we have a 
duty under the Act to maintain a document that gives guidance about licensed activities and the people who 
carry them out. The Code of Practice contains regulatory principles for licensed centres, and guidance notes 
which provides guidance to help clinics deliver safe, effective and legally compliant treatment and research. 
Guidance in the Code of Practice also serves as a useful reference for patients, donors, donor-conceived 
people, researchers and those working in the fertility sector.") [hereinafter CODE OF PRACTICE]. 87 CODE OF PRACTICE, supra note 86, at 11-12 (noting that the Code of Practice contains "mandatory 
requirements[,] .[,] . .  . interpretation of mandatory requirements[,] guidance [and o]ther legislation, 
professional guidelines and information."). 88 See Press Release, Dept. of Health, Fertility and Tissue Regulators to be Reviewed Following Consultation, 
(Jan. 25, 2013) (Eng.),, http:l/mediacentre.dh.gov.uk/2013/01/25/fertility-and-tissue-regulators-to-be­
reviewed-following-consultation/ [https://perma.cc/EH3C-2ZM7]. 89 For more information on the roles of the Human Tissue Authority, Care Quality Commission, and Health 
Research Authority, see id.; DEP'T OF HEALTH, GOVERNMENT RESPONSE TO THE CONSULTATION ON 
PROPOSALS TO TRANSFER FuNCTIONS FROM THE HUMAN FERTILISATION AND EMBRYOLOGY AUTHORITY 
AND THE HUMAN TISSUE AUTHORITY 6-8 (2013), 
https ://assets. publishing. service. gov. uk/ govermnent/uploads/ system/uploads/ attachment_ data/file/212 7 4 2/C 
onsultation _ HFEA _and_ HT A _govermnent_ response. pelf [hereinafter GOVERNMENT RESPONSE] .. For public 
responses to the public consultation related to the continued existence of the HFEA, see DEP 'T OF HEAL TH, 
CONSULTATION ON PROPOSALS TO TRANSFER FuNCTIONS FROM THE HUMAN FERTILISATION AND 
EMBRYOLOGY AUTHORITY AND THE HUMAN TISSUE AUTHORITY: RESPONSES (2013). 90 See David Adamson, Regulation of Assisted Reproductive Technologies in the United States, 39 FAM. L.Q. 
727, 739 (2005); Lyndsey Craven et al., Research into Policy: A Brief History of Mitochondrial Donation, 34 
STEM CELLS 265, 265 (2016); Katherine Drabiak, Emerging Governance of Mitochondrial Replacement 
Therapy: Assessing Coherence Between Scientific Evidence and Policy Outcomes, 20 DEPAUL J. HEALTH 
CARE L. 1, 20 (2018); Gitter, supra note 74, at 1008; Lyria B. Moses, Understanding Legal Responses to 
Technological Change of In Vitro Fertilization, 6 MINN. J.L. SCI. & TECH. 505, 603 (2005) (stating 
"Restrictions on the freedom of clinicians to determine what is best for each individual patient in the context 
of multiple embryo transfer is the most common criticism of HFEA by clinics."); Riley & Merrill, supra note 
74, at 53 ("HFEA has frequently been criticized as overly 'pro-choice."); Helene S. Shapo, Frozen Pre­
Embryos and the Right to Change One's Mind, 12 DUKE J. COMP. & INT'L L. 75, 99 (2002). 91 HUMAN FERTILISATION & EMBRYOLOGY AUTH., ANNUAL REPORT & ACCOUNTS, CHAIR AND CHIEF 
EXECUTIVE'S FOREWORD 4-5 (2012-2013), 
http://www.hfea.gov.uk/docs/HFEA_Annual_Report_and_Accounts_20l2 - l3.PDF [hereinafter CHAIR AND 
CHIEF EXECUTIVE'S FOREWORD];_see GoVERNMENT RESPONSE, supra note 89.). For more on the public 
consultation process in the United Kingdom, see UK CABINET OFFICE, CONSULTATION PRINCIPLES 2018 
(2018). For more on public consultations generally, see Bojan Bugaric, Openness and Transparency in Public 
Administration: Challenges for Public Law, 22 WIS. INT'L L.J. 483, 502-4 (2004); Andrew Edgar, 
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be retained as an independent regulator. .. follow[ing] a public consultation in which 75 
percent of respondents argued that retaining the HFEA as a specialist expert regulator 
was in the best interests of patients and the fertility sector."92 
2. Regulation of Mitochondrial Transfer in the United Kingdom 
In order to legalize the use of mitochondrial transfer in the United Kingdom, 
the UK's govermnent initiated a number of statutory and regulatory changes. The 2008 
Amendment of the Human Fertilisation and Embryology Act "introduce[ed] new 
powers which allow for Regulations to be passed by Parliament that will allow 
techniques that alter the DNA of an egg or embryo to be used in assisted conception, to 
prevent the transmission of serious mitochondrial disease."93 The 2008 Act addresses, 
among other issues, the legal parentage of children conceived as a result of newer forms 
of ART, such as mitochondrial transfer and posthumously conceived children. 94 
Before approving the use of mitochondrial transfer in the United Kingdom, 
however, the HFEA undertook a number of scientific reviews and a five-strand public 
consultation. 95 After a public consultation on the topic of mitochondrial transfer in 
March 2013, the United Kingdom's HFEA "concluded there was 'general support' for 
the idea and that there was no evidence that the advanced form of IVF was unsafe."96 
The UK's five-strand public consultation included a number of information gathering 
methods, including " . . .  deliberative public workshops, . . .  [ a] public representative 
survey, . . .  [ an] open consultation questionnaire, . . .  open consultation meetings . . .  and 
patient focus groups. "97 
The United Kingdom's Department of Health produced draft regulations, and 
an amendment to the Human Fertilisation and Embryology Act was approved by the 
House of Lords at the end of February 2015.98 Sally Cheshire, the chairwoman of the 
HFEA, said: 
Administrative Regulation- Making: Contrasting Parliamentary and Deliberative Legitimacy, 40 MELB. U. L. 
REV. 738, 751-52 (2017). For more on public consultations in the United Kingdom related to assisted 
reproductive technology, see Mary L. Shanley, Collaboration and Commodification in Assisted Procreation: 
Reflections on an Open Market and Anonymous Donation in Human Sperm and Eggs, 36 L. & SOC'Y REV. 
257, 274 n.35 (2002); Benjamin B. Williams, Screening for Children: Choice and Chance in the "Wild West " 
of Reproductive Medicine, 79 GEO. WASH. L. REV. 1305, 1327 (2011). 92 See CHAIR AND CHIEF EXECUTIVE'S FOREWORD, supra note 91, at 4-5; GOVERNMENT RESPONSE, supra 
note 89. 93 HUMAN FERTILISATION & EMBRYOLOGY AUTH., MITOCHONDRIA REPLACEMENT CONSULTATION: ADVICE 
TO GOVERNMENT 8 (2013), https://www.hfea.gov.uk/media/2618/mitochondria_replacement_consultation_­
_advice_for_govermnent.pdf [hereinafter ADVICE TO GoVERNMENT]; see Joan Mahoney, Genome Mapping 
and Designer Babies: A Comparative Perspective, 79 UMKC L. REV. 309, 312 (2010) (discussing the 
scientific and social motivations for the 2008 Amendment to the 1990 Act). 94 See CHAIR AND CHIEF EXECUTNE'S FOREWORD, supra note 92, at 8; Maya Sabatello, Posthumously 
Conceived Children: An International and Human Rights Perspective, 27 J.L. & HEALTH 29, 36 (2014). 
95 ADVICE TO GOVERNMENT, supra note 93, at 7. 96 See James Gallagher, UK Government Backs Three- Parent WF, BBC NEWS (June 27, 2013), 
www.bbc.co.uk/news/health-23079276 [https://perma.cc/5KDD-LP3F]; see also CHAIR AND CHIEF 
EXECUTNE'S FOREWORD, supra note 9 l_(characterizing support for mitochondrial replacement as "broad"). 97 SARAH BARBER & PETER BORDER, MITOCHONDRIAL DONATION 13 (2015), 
https://researchbriefings.files.parliament.uk/documents/SN06833/SN06833.pdf. 98 See Brittany Shoot, 3-parent WF: Why Isn't it Available in the United States?, THE GUARDIAN (Feb. 27, 
2015), http://www.theguardian.com/sustainable-business/2015/feb/27/3-parent-ivf-us-mitochondria-dna­
babies [https://perma.cc/RHM9-96VA]. For more on lawmaking in the UK, see sources cited supra notes 58-
63. 
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Britain is the first country in the world to permit this treatment, and it is a 
testament to the scientific expertise and well-respected regulatory regime that 
exists across the UK that Parliament has felt able to approve it . . .  The HFEA 
has a long tradition of dealing with medical and scientific breakthroughs, 
ensuring that IVF techniques, pioneered in the UK and now practised across 
the world, can be used safely and effectively in fertility treatment. 99 
While notice-and-comment rulemaking is a hallmark of American 
administrative law, the United Kingdom's experience with mitochondrial transfer went 
far beyond notice-and-comment mlemaking in terms of the depth and breadth of the 
UK's consultation and scientific inquiry into mitochondrial transfer. 100 As noted by the 
Parliamentary Office of Science and Technology, "[t]he techniques (maternal spindle 
transfer and pronuclear transfer) have been subject to three scientific reviews (2011, 
2013 and a further update in 2014), [focused on safety and efficacy,] by a Human 
Embryology and Fertilisation Authority expert panel, an ethical review by the Nuffield 
Council on Bioethics and a HFEA public consultation." 101 A fourth scientific review 
was completed in November 2016. 102 The UK's Chief Medical Officer noted, on the 
subject of mitochondrial transfer, "[t]he only clinical tests you can do are either in rats, 
mice and monkeys - and those have been done - or in humans and the mothers now 
want to do this following those three scientific reviews."103 
As noted earlier, the HFEA public consultation consisted of five strands.104 The 
first strand was composed of deliberative public workshops. 105 The first meetings of the 
deliberative public workshops focused on helping members of the public understand the 
science underlying mitochondrial donation techniques and mitochondrial disease, which 99 See Gallagher, supra note 96. 
100 Nina A Mendelson, Rulemaking, Democracy, and Torrents of E-Mail, 79 GEO. WASH. L. REV. 1343, 1343-
44 (2011). 
101 See BARBER & BORDER, supra note 97, at I. For the "three scientific reviews" of mitochondrial transfer 
(and the 2014 addendum to the "further update in 2014"), see generally HUMAN FERTILISATION & 
EMBRYOLOGY Aurn., ANNEX VIII: SCIENTIFIC REVIEW OF THE SAFETY AND EFFICACY OF METHODS TO 
A VOID MITOCHONDRIAL 
DISEASE THROUGH ASSISTED CONCEPTION: UPDATE (2013), https://www.hfea.gov.uk/media/2612/mito ­
annex_viii-science_review_update.pdf; HUMAN FERTILISATION & EMBRYOLOGY Aurn., REVIEW OF THE 
SAFETY AND EFFICACY OF POLAR BODY TRANSFER TO AVOID MITOCHONDRIAL DISEASE ADDENDUM TO 
'THIRD SCIENTIFIC REVIEW OF IBE SAFETY AND EFFICACY OF METHODS TO A VOID MITOCHONDRIAL 
DISEASE THROUGH ASSISTED CONCEPTION: 2014 UPDATE' (2014), 
https://www.hfea.gov.uk/media/2610/2014-10-07 _-_polar_ body _transfer_ review_ -_final.pdf; HUMAN 
FERTILISATION & EMBRYOLOGY AUTH., SCIENTIFIC REVIEW OF THE SAFETY AND EFFICACY OF MEIBODS TO 
AVOID MITOCHONDRIAL DISEASE THROUGH ASSISTED CONCEPTION (2011), 
https://www.hfea.gov.uk/media/2613/scientific-review-of-the-safety-and-efficacy-of-methods-to-avoid­
mitochondrial-disease-through-assisted-conception.pdf; HUMAN FERTILISATION & EMBRYOLOGY Aurn., 
THIRD SCIENTIFIC REVIEW OF THE SAFETY AND EFFICACY OF MEIBODS TO A VOID MITOCHONDRIAL DISEASE 
THROUGH ASSISTED CONCEPTION: 2014 UPDATE, (2014), 
https ://www.hfea.gov. uk/media/2614/third _ mitochondrial_ replacement_ scientific_ review .pdf. 
102 See HUMAN FERTILISATION & EMBRYOLOGY Aurn., SCIENTIFIC REVIEW OF THE SAFETY AND EFFICACY 
OF METHODS TO AVOID MITOCHONDRIAL DISEASE THROUGH ASSISTED CONCEPTION: 2016 UPDATE 4-5 
(2016), https://www.hfea.gov.uk/media/261 l /fourth _scientific _review_ mitochondria_ 2016.pdf [hereinafter 
2016 UPDATE]. 
103 See Steve Connor, Chief Medical Officer Urges Lords to Legalise 'Three- Parent' IVF, THE INDEPENDENT 
(Feb. 24, 2015), http://www.independent.co.uk/news/science/chief-medical-officer-urges-lords-to-legalise­
three-parent-ivf-10065833.html [https://perma.cc/Q2CM-736D]. 
104 See ADVICE TO GOVERNMENT, supra note 93. 
105 See id. at 10-11. 
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could numnuze sensationalism of press coverage. 106 The "second events [of the 
deliberative public workshops] focused on the social and ethical issues relating to the 
techniques." 107 The second strand of the UK's public consultation included nearly 1,000 
face-to-face interviews with members of the public on a number of topics related to 
mitochondrial disease, treatment of genetic disease and ART. 108 Third, open 
consultation meetings "involved a combination of small group discussions around 
particular issues, whole group debates, and discussion between and across the panel and 
the floor." 109 Fourth, the "open consultation questionnaire" permitted interested 
members of the public to consider information posted on a public consultation website 
before submitting responses to seven specific questions through the mail or online. 110 
Fifth, there was a patient focus group, composed of individuals who had been directly 
or indirectly affected by mitochondrial disease. rn The aforementioned five-strand 
public consultation contained a number of methods that parallel the American 
administrative law consultation process or that could be adapted to a public consultation 
in the United States on the topic of mitochondrial transfer, and ultimately, other 
technologies involving genetic modification. 
3. The Role ofNon-Govermnental Bodies 
Non-govermnental bodies such as the aforementioned National Academies of 
Sciences in the United States and the Nuffield Council on Bioethics in the United 
Kingdom aid national govermnents in decision-making related to assisted reproductive 
technology, especially mitochondrial transfer. 112 For example, in one of the Nuffield 
Council's reports, NOVEL TECHNIQUES FOR THE PREVENTION OF MITOCHONDRIAL DNA 
DISORDERS: AN ETHICAL REVIEW, the Nuffield Council on Bioethics " [a]s an 
independent body . . .  sought to identify the novel ethical issues raised [by mitochondrial 
replacement therapies] , while also looking deeper into the issues which have already 
featured in the public debate about these techniques." 113 This Report was cited to in 
numerous influential documents issued by the HFEA and UK Parliamentary offices in 
relation to the UK Parliament's ultimate changing of the regulations to permit the use of 
mitochondrial transfer in the United Kingdom. 114 
B. UNITED STATES 
106 Id. at 1 1, 22. 
107 Id. at 1 1 .  
10s Id. 
109 Id. 
110 See ADVICE TO GOVERNMENT, supra note 93, at 11 .  
1 1 1  Id. 
112 See infra note 160 and accompanying text (discussing the National Academy of Science's report completed 
at the request of the FDA); see also About, NUFFIELD COUNCIL ON BIOEIBICS, 
http://nuffieldbioethics.org/about [https://perma.cc/494C-8ZHS] ("The Nuffield Council on Bioethics is an 
independent body that examines and reports on ethical issues in biology and medicine. It was established by 
the Trustees of the Nuffield Foundation in 1991, and since 1994 it has been funded jointly by the Foundation, 
Wellcome and the Medical Research Council. The Council has achieved an international reputation for 
advising policy makers and stimulating debate in bioethics.") 
113 NUFFIELD COUNCIL ON BIOEIBICS, NOVEL TECHNIQUES FOR IBE PREVENTION OF MITOCHONDRIAL DNA 
DISORDERS: AN EIBICAL REVIEW viii (2012), http://nuffieldbioethics.org/wp­
content/uploads/2014/06/Novel_techniques _for _the _prevention_ of_ mitochondrial_ DNA_ disorders_ compre 
ssed.pdf. 
114 See ADVICE TO GOVERNMENT, supra note 93 at 10; 2016 UPDATE, supra note 102 at 32; BARBER & 
BORDER, supra note 97, at 5 (stating "information . . .  to Members of Parliament in support of their 
parliamentary duties"). 
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While the United Kingdom was the site of the birth of the first child 
conceived using ART, many innovations in ART have developed in the United States. 
In 2014, there was significant media coverage of the work of Dr. Shoukhrat Mitalipov 
at the Oregon Health & Science University in the realm of maternal spindle transfer, one 
of the two forms of mitochondrial transfer. 1 15 More recently, Dr. John Zhang, a New 
York-based physician traveled to Mexico to prevent the transmission of Leigh 
Syndrome, a mitochondrial disease, using mitochondrial transfer. 116 Before that in the 
1990s and early 2000s, a number of American physicians were providing cytoplasmic 
transfer, which was similar to mitochondrial transfer, in order to improve women's 
fertility. 117 Yet, in all of these aforementioned instances, innovation was stymied in 
several ways. The FDA sent letters to physicians providing cytoplasmic transfer, stating 
that in order to continue providing these techniques to their patients, they had to obtain 
approval through the FD A's investigational new drug approval process.118 In the case of 
more recent innovations in mitochondrial transfer, the FDA responded with continued 
declarations of its jurisdiction over the technique through letters to physicians and 
general declarations. 119 Subsequently, Congressional budget riders have prohibited the 
agency from considering licenses for ART techniques involving genetic modification. 120 
This part explores both the federal and state regulation of ART (including advanced 
assisted reproductive technologies) in the United States. 
1. The American Regulatory Framework Governing Assisted Reproductive 
Technology Use and Innovation 
Historically, there has been little state or federal regulation of ART, which 
allowed the industry to develop with little regulatory oversight. 121 The prevailing view 
is that ART in the United States is minimally regulated or unregulated; however, forms 
of ART involving genetic modifications are highly regulated in the United States, albeit 
through formally non-binding documents issued by the federal government that 
nonetheless have practically binding effects. 122 For those forms of ART that are more 
115 Sabrina Tavernies, His Fertility Advance Draws Ire, N.Y. TIMES (Mar. 17, 2014). 
116 See John Zhang et al., Live Birth Derived from Oocyte Spindle Transfer to Prevent Mitochondrial Disease, 
34 REPROD. BIOMEDICINE ONLINE 361, 361-68 (2017) (discussing the use of mitochondrial donation treatment 
in a patient with Leigh Syndrome by Dr. John Zhang and other colleagues at the New Hope Fertility Center, 
which has offices in New York and Mexico). 
117 See Subterranean Regulation, supra note 5, at 1250, 1260; see also Charlotte Pritchard, The Girl with Three 
Biological Parents, BBC NEWS: MAG (Sept. 1, 2014), https://www.bbc.com/news/magazine-28986843 
[https:/ /perma.cc/HK49-M7 4 V]. 
118 Subterranean Regulation supra note 5, at 258. For the full letter, see id. at 1289-91. 
119 See Letter from Mary A Malarkey, Dir., Office of Compliance & Biologics Quality, Ctr. for Biologics 
Evaluation & Research, U.S. Food & Drug Admin., to John Zhang, CEO, Darwin Life, Inc. & New Hope 
Fertility Center (Aug. 4, 2017), https://www.fda.gov/media/106739/download [hereinafter FDA Letter]; see 
also Advisory on Legal Restrictions on the Use of Mitochondrial Replacement Techniques to Introduce Donor 
Mitochondria into Reproductive Cells Intended for Transfer into a Human Recipient, Cellular & Gene Therapy 
Products, U.S. FOOD & DRUG ADMIN. (Mar. 16, 2018), 
https ://www.fda.gov/biolo gicsb loodvaccines/ cellulargenetherapyproducts/ucm5 70 185 .htm 
[https://perma.cc/RW6M-S9EN] ("The clinical use of [mitochondrial replacement therapy] in the United 
States falls within FD A's regulatory authority.") [hereinafter MRT Legal Restrictions]. 
120 See, e.g., FDA Letter, supra note 119; MRT Legal Restrictions, supra note 119. 
121 Lori B. Andrews & Nanette Elster, Regulating Reproductive Technologies, 21 J. LEGAL MED. 35, 35-44 
(2000) (providing historical overview of ART). 
122 See Subterranean Regulation, supra note 5, at 1241 n.l ,  1259, 1270; see also Heled, supra note 27, at 247 
(noting the "dearth of state law and a total lack of federal law regulating the genetic aspects of [ donated 
reproductive tissue]"); Rosato, supra note 36, at 57, 63 ("Assisted reproductive technology ('ART') has been 
in existence for twenty-five years with very little oversight or regulation." (citations omitted)). 
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"traditional," and similar to the ART of the 1970s, such as IVF (without genetic 
modifications) and artificial insemination, the traditional characterization of the 
regulation of ART remains accurate as states and the federal govermnent provide little 
regulation of ART that does not involve genetic modification. 123 
As noted in part II.B supra, the Fertility Clinic Success Rate and 
Certification Act is the only federal statute that regulates ART.124 In spite of the 
existence of only one statute that applies to ART regulation, 125 the FDA has used its 
power to stymie the use of forms of ART that involves genetic modifications in the 
United States. 
First, the agency used notice-and-comment rulemaking to promulgate its 
Human Cellular and Tissue-Based Products regulation, which became a final rule in 
2001.126 This final rule created a framework in which "more than minimally 
manipulated" tissue is subject to the agency's investigational new drug requirements. 127 
Despite comments received during the notice-and-comment rulemaking process stating 
that the term "minimal manipulation" was vague and should be eliminated, the agency 
retained the term and its associated framework. 128 Ultimately, that framework has been 
applied to innovations in ART, which are characterized by the FDA as involving "more 
than minimal manipulation," thus requiring the use of an investigational new drug 
application under federal law, instead of being categorized as simply the practice of 
medicine. 129 
Subsequent to the effective date of the Human Cellular and Tissue-Based 
Products rule, the agency issued a number of documents, based on that regulation, 
stating that the agency has jurisdiction over forms of ART involving genetic 
modification, without clearly explaining what statutes accorded it such jurisdiction. 130 
123 See Subterranean Regulation, supra note 5, at 1270-71 n.136. 
124 See 42 U.S.C. § 263a-l (2012). 
125 See id. 
126 See Human Cells, Tissues, and Cellular and Tissue-Based Products; Establishment Registration and Listing, 




127 Human Cells, Tissues, and Cellular and Tissue-Based Products; Establishment Registration and Listing, 66 
Fed. Reg. at 5452. 
128 Id. at 5457 ("Eight comments asserted that 'minimal manipulation' is vague and open to subjective 
interpretation, and should be eliminated. Two comments asserted that it is difficult to draw a meaningful 
distinction between tissues that are minimally manipulated and those that are more than minimally 
manipulated. One of these comments suggested that instead of the minimal manipulation criterion, FDA 
should propose that tissue products labeled or promoted for tissue replacement, reconstruction, or restoration 
of function be regulated as tissue. Another comment requested the development of guidance and noted that, 
in light of future technological advances, a broader definition of minimal manipulation may be more 
appropriate."). Overall, the FDA received "28 comments on the proposed rule as it was published in 1998 
[and] over 400 comments on the donor-suitability proposed rule; many of these raised issues related to subparts 
A and B of part 1271." Id. at 5450. Comments related to the term "minimal manipulation" were addressed 
with the other comments on Comments on Subpart A: Proposed Sectionl 271.10 and Section 1271.15 (Final 
Section 1271.10 and Section 1271.20). Id. at 5450, 5453, 5457. 
129 See Halted Innovation, supra note 7, at l lOO. 
130 See id. § 553(b)(3) ("Except when notice or hearing is required by statute, this subsection [requiring notice 
of proposed mlemaking] does not apply . . .  to interpretive mies, general statements of policy, or mies of 
agency organization, procedure, or practice"); see also Advisory on Legal Restrictions on the Use of 
Mitochondrial Replacement Techniques to Introduce Donor Mitochondria into Reproductive Cells Intended 
for Transfer into a Human Recipient, Cellular & Gene Therapy Products, U.S. FOOD & DRUG ADMIN. (Mar. 
16, 2018), https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/ucm570185 .htrn 
[https://perma.cc/9STE-Q4LF]. 
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These documents, issued by the FDA, were part of a larger trend in which many agency 
decisions escape notice-and-comment rulemaking, thereby eliminating the opportunity 
for the public to provide comments on proposed federal regulations and agency action. 13 1 
As numerous scholars have noted, many agencies rely upon informal methods 
of guidance to regulate, instead of issuing mles. 132 First, informal guidance methods are 
not subject to public comment. 133 Second, their informal nature makes it much harder 
for the public to rely on those mechanisms or to even know that those mechanisms exist 
although, at the same time, various court opinions have noted that guidance documents 
have binding effect even though they are not subject to the notice-and-comment process 
and contain disclaimers stating that they are not binding. 134 Although assisted 
reproductive technology providers have not commenced litigation related to the FD A's 
pronouncements on the effects "minimal manipulation" framework as detailed in non­
legislative documents to assisted reproductive technology, it is worth noting that a 
significant amount of administrative law literature and court decisions have focused on 
ascertaining when agency pronouncements should be categorized as legislative rules, 
which are subject to notice-and-comment mlemaking, as opposed to as interpretive or 
non-legislative rules which are not. 135 While some regulated entities appreciate informal 
agency pronouncements because those announcements permit them to perhaps cease 
actions that might result in domestic enforcement actions, 136 others are troubled by these 
131 See WILLIAM N. ESKRIDGE JR., STATUlES, REGULATION, AND lNlERPRETATION: LEGISLATION AND 
ADMINISTRATION IN IBE REPUBLIC OF STATUTES 713-16, 838 (2014). 
132 Id. at 838; Richard A. Epstein; The Role of Guidances in Modern Administrative Procedure: The Case for 
De Novo Review, 8 J. OF LEG. ANALYSIS 47, 47-48, 58-83 (2016) (discussing the evolution of the current use 
of guidance documents by administrative agencies); David L. Franklin, Legislative Rules, Nonlegislative 
Rules, and the Perils of the Short Cut, 120 YALE L.J. 276, 278, 286-89 (2010); Matk Seidenfeld, Substituting 
Substantive for Procedural Review of Guidance Documents, 90 TEX. L. REV. 331, 332-8 and 340-4 (2011). 
133 Epstein, supra note 132, at 47. 
134 Halted Innovation, supra note 7, at 1098. 
135 See e.g. Matk Seidenfeld, Substituting Substantive for Procedural Review, 90 TEX. L. REV. 331, 332 and 
350-2; Id. at 360-1 ("For interpretive mies, the message from the courts is that the weaker the link between 
the interpretation and the text of the statute or regulation being interpreted, the less likely a court is to allow 
the agency to announce the interpretation by guidance document."); Perez v. Mortgage Bankers Ass'n, 135 S. 
Ct. 1199, 1208 (2015); Appalachian Power Co. v. EPA, 208 F.3d 1015, 1021 and 1024-5 (2000); General 
Electric Co. v. EPA, 290 F.3d 377, 380-85 (2002); Nat'! Min. Ass'n v. Sec'y of Labor, 589 F.3d 1368, 1371-
73 (2009). For more on the disparate tests used to ascertain whether a document that the agency has classified 
as a non-legislative rule actually required notice-and-comment because it actually should have been issued as 
a legislative rule, see e.g. Kristin Hickman, Unpacking the Force of Law, 66 VAND. L. REV. 465, 480-84 
(2013); Id. at 503 at n. 205, 513; David L. Franklin, Legislative Rules, Nonlegislative Rules, and the Perils of 
the Short Cut, 120 YALE L. J. 276, 284 (2010)(discussing the concern that agencies "strategically" use non­
legislative documents to avoid the notice-and-comment rulemaking process and the various tests that courts 
use to ascertain whether a "document promulgated without notice and comment is really a legislative rule and 
is therefore procedurally invalid," including the "legal effect test" and the "substantial impact test."). See also 
Kelley v. E.P.A., 15 F.3d 1100, 1108 (D.C. Cir. 1994); Appalachian Power Co. v. EPA ("We must still look 
to whether the interpretation itself carries the force and effect of law, .. or rather whether it spells out a duty 
fairly encompassed within the regulation that the interpretation purports to construe" citing to Paralyzed 
Veterans v. D.C. Arena L.P., 117 F. 3d 579, 588 (D.C. Cir. 1997). See also infra note 131. 
136 Subterranean Regulation, supra note 5, at 1259-60 (describing the reactions of physician-researchers after 
receiving letters from the FDA which was to cease their research or medical practice or move it abroad). 
Beyond the reactions of physicians and researchers after receiving letters from the FDA, examining the 
agency's letters through the lens of the tests that courts have used to ascertain whether guidance documents 
should be treated as legislative mies, many aspects of those agency rules lend themselves to arguments that 
the agency documents explaining the application of the "minimal manipulation rule" should be treated as 
legislative mies as opposed to non-legislative mies. For example, while the FDA's letters to researchers in 
2001 did not specifically state that their specific work was subject to the FDA's regulation, the letter used 
mandatory language: "The use of such genetically manipulated cells (and/or their derivatives) in humans 
152 AMERICAN JOURNAL OF LAW & MEDICINE VOL. 45 NO. 2-3 2019 
informal agency pronouncements because they create an uncertainty, having provided 
an agency view in a non-binding document. 137 The goal of notice-and-comment 
regulations is said "to discipline agency decision making and promote public-regarding 
(i.e., nonarbitrary) action by agencies," although many types of decisions, including 
nonenforcement decisions and decisions supported by guidance documents, are not 
subject to public comment. 138 
Congressional budget riders can also stymie innovation. Congress has enacted 
(and renewed annually) budget riders that restrict the funding of certain embryonic stem 
cell research projects since 1996, and the FDA's review of applications involving 
genetic modification since 2015.139 These riders have been enacted without a defined 
consultation with the public on these matters and in at least one case, without any 
constitutes a clinical investigation and requires submission of an Investigational New Drug application (IND) 
to FDA." Letter from U.S. Food & Drug Admin., to Sponsors/Researchers - Human Cells Used in Therapy 
Involving the Transfer of Genetic Material by Means Other Than the Union of Gamete Nuclei (May 6, 2009); 
see e.g.Ronald M. Levin, Rulemaking and the Guidance Exemption, 70 ADMIN. L. REV. 263, 294-98 (2018) 
(discussing courts' analysis of mandatory language in litigation related to whether agency documents are in 
fact legislative mies despite being labeled otherwise). The reactions of physicians and researchers to the 
FD A's letters which purport to "advise" addressees of the agency's jurisdiction and requirements indicates 
that those letters and the agency's interpretations have "the force and effect of law." See Am. Mining Cong. 
v. Mine Safety & Health Admin., 995 F.2d 1106, 1108-09 (D.C. Cir. 1993). For those who received the 
agency's letters in 2001, they stopped providing the technique in the United States. Similarly, in 2017, Dr. 
John Zhang, who provided the technique in Mexico, to avoid the U.S. regulatory system, later submitted an 
investigational new drug application so as to offer the technique in the United States in accordance with the 
FDA's statements of what was required by the statute (as explained through the Human Cellular and Tissue­
based Products rule and the agency's subsequent pronouncements in non-legislative documents). See supra 
note 116 and accompanying text. In sum, the effect of these agency statements regarding its jurisdiction over 
forms of assisted reproductive technology involving genetic modification is that researchers adhere to the 
FDA's framework, as explained in guidance documents and either cease offering (and researching) the 
technique altogether or cease offering the technique in the United States specifically in order to avoid the 
FD A's jurisdiction. Thus, these agency interpretations carry the "force and effect of law." See Appalachian 
Power Co. v. EPA, 208 F.3d 1015, 1024 (2000); but see Perez v. Mortgage Bankers Assoc., 135 S. Ct. 1199, 
1207-11 (2015) (explaining that agencies do not have to use notice-and-comment mlemaking when 
"significantly alter[ing] a prior, definitive interpretation of a regulation'' as was previously required by 
Paralyzed Veterans);). But see Gwendolyn Mc Kee, Judicial Review of Agency Guidance Document: 
Rethinking the Finality Doctrine, 60 ADMIN. L. REV. 371, 380, 390-97 7(discussing the FDA's statutory 
disclaimer related to the binding nature of guidance documents and litigation related to guidance documents 
in the context of the FDA). For post-Perez discussion of various tests still used to interpret whether an agency 
decision is a legislative or non-legislative rule, see generally Ronald M. Levin, Rulemaking and the Guidance 
Exemption, 70 ADMIN. L. REV. 263 (2018); Cass R. Sunstein, "Practically Binding ": General Policy 
Statements and Notice- and- Comment Rulemaking, 68 ADMIN. L. REV. 491, 505-088 (2016). 
137 See Subterranean Regulation, supra note 5. 138 See Deacon, supra note 41, at 1591. 139 See George Q. Daley, Missed Opportunities in Embryonic Stem- Cell Research, Perspective, 351 N. ENG. 
J. MED. 627, 628 (2004) ("Proposed in 1996 by Representative Jay Dickey (R-Ark.) as a rider on the 
appropriations bill for the Department of Health and Human Services and renewed every year since, the 
Dickey[ -Wicker] Amendment prohibits federal engagement in a field of research pertaining to the nature of 
the human embryo, its disorders of development, and the derivation of new human embryonic stem-cell lines. 
Although most embryos created in vitro during fertility procedures are deemed unsuitable for pregnancy and 
are discarded, federal funds may not be used to ascertain what went wrong."); FDA Letter, supra note 119 
("Since December 2015, the United States Food and Drug Administration (FDA) has been prohibited by 
Congress in provisions in annual federal Appropriations Acts from using funds to accept IND submissions for 
clinical investigations that involve 'a human embryo .. .  intentionally created or modified to include a heritable 
genetic modification."); see also The Consolidated Appropriations Act, 2017, Pub. L. No. 115-31, 131 Stat. 
173 (2017). For more on the aforementioned Consolidated Appropriations Act provision, see generally I. 
Glenn Cohen & Eli Y. Adashi, The FDA is Prohibited From Going Germline, 353 SCIENCE 545 (2016). 
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discussion of the rider itself at all. 14° For example, Professor June Carbone noted in 
2010, "[g]iven the federal ban on funding embryo research, any preapproval process is 
likely to delay if not permanently stall the development of new techniques." 141 Even 
though some embryonic stem cell research is now federally funded, it is subject to a 
number of limitations, including limits on available stem cell lines for research and 
federal appropriations restrictions like the Dickey-Wicker Amendment, which aims to 
prevent research on embryos that can result in their destmction. 142 
Thus, Congressional action suffers from a lack of discourse on the ethical and 
social issues surrounding stem cell research and forms of ART.143 In the case of 
mitochondrial transfer, although this article focuses on the varying approaches of the 
United States and United Kingdom regarding mitochondrial transfer, this form of ART 
has been offered to patients in other countries, including Mexico. 144 The fact that a New 
York based physician traveled to Mexico to provide mitochondrial transfer to a couple 
was the subject of media attention not only after the successful birth of a child, but also 
in 2017 when the FD A denied the application of the physician for an investigational new 
drug application, citing a federal budget rider that prevented them from expending funds 
related to applications for investigational new drug applications involving genetic 
modification. 145 
140 For more on the "scant" legislative history of the Dickey-Wicker Amendment and the surrounding 
discussion, see Kerry L. Macintosh, Psychological Essentialism and Opposition to Human Embryonic Stem 
Cell Research, 18 J. TECH. L. & POL'Y 229, 252-57 (2013); see also Eli Y. Adashi & I. Glenn Cohen, 
Mitochondrial Replacement Therapy: Unmade in the USA, 317 JAMA 555, 574-75 ("The congressional 
record is mum on the identity of the sponsor or sponsors of the ban ['which comprises Section 749 of the 
Consolidated Appropriation Act of 2016 '], and the precise motives for crafting it remain equally uncertain. 
The ban's enactment was all but guaranteed by the complete absence of discussion before its passage or at any 
time thereafter, and by its inclusion in a must-pass omnibus appropriation bill."); Kiyan Bigloo, Aggregation 
of Powers: Stem Cell Research and the Scope of Presidential Power Examined Through the Lens of Executive 
Order Jurisprudence, 18 PSYCHOL. PuB. POL'Y & L. 519, 522-26 (2012); Advisory on Legal Restrictions on 
the Use of Mitochondrial Replacement Techniques to Introduce Donor Mitochondria into Reproductive Cells 
Intended for Transfer into a Human Recipient, U.S. FOOD & DRUG ADMIN. (Mar. 16, 2018), 
https ://www.fda.gov/biolo gicsb loodvaccines/ cellulargenetherapyproducts/ucm5 70 185 .htm 
[https://perma.cc/9STE-Q4LF] ("Since December 2015, Congress has included provisions in annual federal 
appropriations laws that prohibit FD A from accepting applications for clinical research using MR T. Therefore, 
clinical research using MRT in humans cannot legally proceed in the United States. FDA maintains the 
authority to investigate and take enforcement action in the event that it becomes aware of noncompliance with 
the laws and regulations administered by FDA"). 
141 June Carbone, Negating the Genetic Tie: Does the Law Encourage Unnecessary Risks?, 79 UMKC L. REV. 
333, 354 (2010). 
142 See George Annas, Resurrection of a Stem- Cell Funding Barrier - Dickey-Wicker in Court, 363 N. ENG. 
J. MED. 1687, 1687-8 (2010) ("The amendment, known as the Dickey-Wicker amendment, provides that no 
federal funds can be expended by the National Institutes of Health (NIH) for ' ( l )  the creation of a human 
embryo or embryos for research purposes; or (2) research in which a human embryo or embryos are destroyed, 
discarded, or knowingly subjected to risks of injury or death.' It has been added to NIH appropriations bills 
every subsequent year, just as the Hyde Amendment restricting abortion fnnding is added."); Stem Cell 
Information Home Page, 2016, NAT'L INST. OF HEALTH, https://stemcells.nih.gov/research/newcell_qa.htm 
[https://perma.cc/5YUZ-DR5W] ("No federal funds may be used, either by an awardee or a sub-recipient, to 
support research using derivatives of human embryonic stem cell lines (hESCs) that are not listed on the NIH 
Human Embryonic Stem Cell Registry, with the exception described below."); see also FDA Letter, supra 
note 119. 
143 See Eli Y. Adashi & I. Glenn Cohen, Preventing Mitochondrial Diseases: Embryo- Sparing Donor­
Independent Options, Opinion, 24 TRENDS IN MOLECULAR MED. 449, 450 at Box 2 (2018) (citing to the 
"theological, ethical, and safety concerns surrounding mitochondrial transfer"). 
144 See Michelle Roberts, First 'Three Person Baby'Baby' Born Using New Method, BBC NEWS (Sept. 27, 
2016), https://www.bbc.com/news/health-37485263 [https://perma.cc/R5Q2-QCZ4]. 
145 See FDA Letter, supra note 119. 
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While much has been written about the risk of agencies being captured by the 
industries that they regulate, the example of ART regulation in the United States raises 
an additional variation on agency capture. 146 In the realm of traditional ART and 
advanced assisted reproductive technologies, the problem is not capture by the industry 
(with the industry being the fertility industry or perhaps providers of ART), but perhaps 
a type of undue political influence by the executive or groups motivated by specific, 
conservative political or social views. For example, issues that tends to surface in 
connection with the use of ART, especially innovative ART, are ethical debates related 
to the morality of destroying embryos and fetuses and political debates related to the 
"personhood" movement, which often surfaces decisions related to the regulation of 
techniques that could destroy embryos or fetuses. 147 
The FDA has acknowledged the existence of social and ethical issues in the 
realm of ART; however, the agency does not create fora for the discussion of those 
issues. For example, at a 2014 FDA Advisory Committee meeting at the 2014 FDA 
Cellular, Tissue, and Gene Therapies Advisory Committee meeting, on the topic of 
mitochondrial transfer, an FDA employee stated that 
[t]he FDA recognizes [that there are] moral, ethical, and 
social policy issues related to genetic modification of eggs and embryos, 
and that these issues have the potential to affect regulatory decisions. However, 
these issues are outside of the scope of this advisory committee meeting. 148 
In spite of the acknowledgment that ethical and social policy issues could "affect 
regulatory decisions[,]" there was no further identification of what exactly those "moral, 
ethical, and social policy issues" were or a subsequent meeting to discuss these issues 
generally or how they might "affect regulatory decisions" specifically. 149 By not 
discussing the moral, ethical, and social policy issues that can impact regulatory 
decisions, the administrative state allows conservative moral, ethical, and social policy 
issues to be the default view of the administrative state: conservative perspectives would 
desire the halting of innovation in ART and the current system supports that goal by not 
assessing whether other views might be relevant ( or prevalent). At least in the realm of 
ART, and also a number of associated technologies including gene editing and 
technologies that result in germline modifications, social groups or at the very least, 
146 Deacon, supra note 41, at 160 l ;  Lyria B. Moses, Understanding Legal Responses to Technological Change: 
The Example of in Vitro Fertilization, 6 MINN. J.L. SCI. & TECH. 505, 581-82 (2005). 
147 See June Carbone & Naomi Calm, Embryo Fundamentalism, 18 WM. &MARY BILLRTS. J. 1015, 1017-18 
(2010); I. Glenn Cohen & Eli Y. Adashi, Embryo Disposition Disputes: Controversies and Case Law, 46 
HASTINGS C1R. REP. 13, 15-16 (2016); Janet L. Dolgin, Embryonic Discourse: Abortion, Stem Cells, and 
Cloning, 31 FLA. ST. U. L. REV. 101, 104-06, 146 (2003); Michele Goodwin, Fetal Protection Laws: Moral 
Panic and the New Constitutional Battlefront, 102 CAL. L. REV. 781, 785 (2014); King, supra note 27, at 323 
("Political debate over embryo creation and destruction often causes people to retreat to their firmly entrenched 
positions on abortion, which contributes significantly to the regulatory stalemate with respect to ART in the 
United States." (citation omitted)); Maya Manian, Lessons from Personhood's Defeat: Abortion Restrictions 
and Side Effects on Women's Health, 74 OHIO ST. L.J. 75, 77 (2013); Mary Ziegler, Beyond Balancing: 
Rethinking the Law of Embryo Disposition, 68 AM. U. L. REV. 515, 523-24 (2018). 
148 U.S. FOOD & DRUG ADMIN., TRANSCRIPT OF CENTER FOR BIOLOGICS EVALUATION AND RESEARCH, 
CELLULAR, TISSUE, AND GENE THERAPIES ADVISORY COMMITTEE MEETING #59 13 (2014) [hereinafter 
MEETING #59 TRANSCRIPT]. 
149 Id.; see Subterranean Regulation, supra note 5, at 1271-74. 
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conservative social views, have managed to capture the regulatory process. 150 If the 
federal government is going to continue to make decisions that likely involve some sort 
of ethical viewpoint, it is important to note that different polities have different ethical 
views. Thus, to the extent that administrative agencies are seen as more transparent than 
Congress, one option is to proceed in a manner that allows for that transparency through 
notice-and-comment, instead of allowing agency staff to make regulatory decisions 
related to assisted reproductive technology without public input. 
In addition to federal regulation, there are numerous state statutes that address 
AR T.151 Some states have mandated insurance coverage of fertility treatments or the 
offer of insurance coverage of fertility treatments. 152 Some states have clarified the 
extent to which insurance coverage does or does not mandate coverage of fertility 
treatments. 153 States have also enacted statutes requiring that fertility clinics inform 
patients of the clinics' success rates related to the success of fertility treatments. 154 Just 
as states can influence other states, they can also impact the federal government. 155 For 
example, many scholars have noted that the Patient Protection and Affordable Care Act 
was based on the state of Massachusetts' insurance scheme. 156 Similarly, in the realm of 
ART, the federal government now provides insurance coverage for infertility treatments 
(including ART) for certain members of the military with service-related disabilities, 
although ART remains otherwise uncovered at the federal level. 157 
150 Wolf et al., supra note 8, at 73 ("The FDA has also recognized ethical and social policy issues related to 
genetic modification of eggs and embryos that will likely affect regulatory decisions."); NIH Statement on 
NIH Funding on Research Using Gene- Editing Technologies in Human Embryos, NAT'L INST. OF HEALTH 
(Apr. 28, 2015), http://www.nih.gov/about-nih/who-we-are/nih-director/statements/statement-nih-funding­
research-using-gene-editing-technologies-human-embryos [https://perma.cc/4WK9-L246] ("However, NIH 
will not fund any use of gene-editing technologies in human embryos. The concept of altering the human 
germline in embryos for clinical purposes has been debated over many years from many different perspectives, 
and has been viewed almost universally as a line that should not be crossed."). 
151 See Sonia M. Suter, The "Repugnance'" Lens of Gonzales v. Carhart and Other Theories of Reproductive 
Rights: Evaluating Advanced Reproductive Technologies, 76 GEO. WASH. L. REV. 1514, 1516 (2008) 
(discussing the role of states in regulating assisted reproductive technology). 
152 See State Laws Related to Insurance Coverage for Infertility Treatment, NAT'L CONFERENCE STATE 
LEGISLATURES (Apr. 27, 2018), http://www.ncsl.org/research/health/insurance-coverage-for-infertility­
laws.aspx# l [https://perma.cc/Z9TX-XU9U] (providing "state laws that require insurers to either cover or 
offer coverage for infertility diagnosis and treatment"). 
153 LA. REV. STAT. § 22:1036 (2009) (describing "[p]rohibited exclusion of coverage of correctable medical 
conditions on basis of infertility"); MINN. STAT. § 256B.0625(13)(a) (2018) (stating "[m]edical assistance 
covers drugs, except for fertility drugs when specifically used to enhance fertility"). 
154 See Calandrillo & Deliganis, supra note 76, at 330 (citing VA. CODE § 54.1-2971.1). 
155 Miriam Seifter, States as Interest Groups in the Administrative Process, 100 VA. L. REV. 953, 993-94 
(2014) ("Phrased another way, federal agencies can work toward fulfilling their expertise-oriented role by 
harnessing the information production machine of the federal system--not from abstract arguments regarding 
principles of federalism, which may well be beyond the administrative ken, but from the specific, diverse 
experiences and information generated by individual states." (citations omitted)). 
156 See Gillian E. Metzger, Federalism Under Obama, 53 WM. & MARY L. REV. 567, 602 (2011); Stephen M. 
Weiner, Payment Reform After PP A CA: Is Massachusetts Leading the Way Again?, 11 YALE J. HEAL TH POL'Y 
L. & ETHICS 33, 33, 33 n.3 (2011). 
157 See DEP'T. VETERANS AFFS., VETERANS HEALTH AFFAIRS DIRECTIVE 1332: INFERTILITY EVALUATION 
AND TREATMENT 1-2 (2017), https://www.va.gov/vhapublications/ViewPublication.asp?pub _ ID=543 l 
[https://perma.cc/FDM9-V5G9] ("establish[ing] policies and procedures for providing infertility evaluation 
and treatment to Veterans enrolled in the Department of Veterans Affairs (VA) healthcare system."); see 
generally Katie Falloon & Philip M. Rosoff, Who Pays? Mandated Insurance Coverage for Assisted 
Reproductive Technology, 16 AM. MED. Assoc. J. OF ETHICS 63, 63 (2014) ("Currently, only about a third of 
states have mandated insurance coverage of infertility treatment, but the vast majority of health insurance 
plans in other states do not offer coverage; hence, most people pay out of pocket. Furthermore, Medicaid does 
not pay for ART anywhere in the US" (citations omitted)); Assisted Reproductive Services, TRICARE (Oct. 
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In addition to professional societies in the United States, just as in the United 
Kingdom, non-governmental bodies in the United States provide useful advice to 
governmental and professional bodies.158 While innovation in ART has been delayed, at 
least as it relates to ART involving genetic modifications at the federal level, there is 
still discussion of the techniques by scientists, scholars, the media, and ethicists, but that 
discussion does not include those in federal government who would be making decisions 
related to the clinical use of ART. In the United States, the closest that the public has 
had to a centralized public discourse in health care on new techniques involving genetic 
modification is a National Academy of Sciences Report.159 At the FDA's request, the 
National Academy of Sciences convened a committee that wrote a report on the "ethical, 
social, and policy issues" implicated by the use of mitochondrial transfer. 160 The 
National Academy of Science's Institute of Medicine's 2016 report recommended the 
use of mitochondrial transfer under specific conditions. 161 Nonetheless, a public 
consultation on ART involving genetic modification still has not occurred and advanced 
assisted reproductive technology innovation continues to be hindered by the American 
administrative state. 
IV. IMPLICATIONS OF THE UNITED STATES' DEMOCRATIC DEFICIT 
There are at least three broader implications of the American democratic deficit 
in ART innovation. First, the regulation of advanced assisted reproductive technologies 
by an administrative agency without public input undermines a number of administrative 
law values such as transparency, legitimacy, and accountability. 162 Second, the lack of 
transparency and public involvement has permitted political concerns to affect scientific 
decision-making as agency employees are able to obfuscate the impact of political and 
social concerns on regulatory decision-making, especially when science is the subject 
of the regulatory regime. Third, as a matter of outcome, a comparative analysis reveals 
that regulation in the United Kingdom has encouraged innovation, which runs counter 
to the prevailing view that regulation had adverse effects on innovation, whereas in the 
3, 2018), https://www .tricare.mil/CoveredServices/IsltCovered/ AssistedReproductiveServices 
[https://perma.cc/6VVR-D292] ("To be medically necessary means it is appropriate, reasonable, and adequate 
for your condition. and combined with natural conception."). 
158 See sources cited infra note 160 and accompanying text (discussing the National Academy of Science's 
report completed at the request of the FDA). 
159 THE NAT'L ACADS. OF SCI., ENG'G & MED., MITOCHONDRIAL REPLACEMENT TECHNIQUES: ETHICAL, 
SOCIAL, AND POLICY CONSIDERATIONS (2016) [hereinafter MRT REPORT]. For a summary of the 2016 
National Academy of Sciences report, see Adashi & Cohen, supra note 143, at 450 Box 2. 
160 MRT REPORT, supra note 159, at ix, 2 ("The proposed investigation and potential clinical use of 
mitochondrial replacement techniques (MR T) raises a novel collection of ethical, social, and policy issues. At 
the request of the U.S. Food and Drug Administration (FDA), the National Academies of Sciences, 
Engineering, and Medicine convened a committee with diverse interdisciplinary expertise and a range of 
backgrounds to examine and analyze these issues, make recommendations regarding whether and how to go 
forward with MR T, and elaborate principles for initial clinical investigations involving these novel techniques 
for avoiding some types of inherited mitochondrial DNA (mtDNA) diseases."). 
161 Id. at xv-xi. 
162 See Richard A. Bierschbach & Stephanos Bibas, Notice- and- Comment Sentencing, 97 MINN. L. REV. 1, 20 
(2012); Seifter, supra note 19, at 1308; Evan J. Criddle, When Delegation Begets Domination: Due Process 
of Administrative Lawmaking, 46 GA. L. REV. 117, 123 (2011); Rose-Ackerman, supra note 21, at 439; Seifter, 
supra note 19, at 1308. 
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United States, regulation has operated to the detriment of innovation in the realm of 
advanced assisted reproductive technologies. 163 
There are a number of aspects of American regulation of ART that defy the 
traditional administrative law goals. Transparency is one of the goals of administrative 
law that often surfaces in the literature analyzing the actions of administrative 
agencies. 164 For example, the Administrative Procedure Act contains statutory 
requirements including "notice-and-comment" mlemaking procedures which operate to 
provide democratic inputs into the administrative process. 165 To the extent that one of 
the goals of administrative law and constitutional law is to "reconcile established legal 
traditions with pragmatic efforts to better balance expertise and accountability with the 
protection of individual rights," the current system has led to a lack of expertise, 
accountability, and protection of individual rights in the realm of advanced assisted 
reproductive technology innovation.166 
While administrative law, especially in the United States, purports to address 
the detailed implementation of the legislature's directives, administrative law "also 
concerns the democratic legitimacy of government policymaking. A fair and open 
policymaking process helps democratic citizens hold modem government accountable 
in the face of demands for delegation and regulation, both within and beyond the 
state." 167 Yet, as noted in parts II and III supra, a large piece of the "[f]air and open 
policymaking process" is missing in the regulation of ART in the United States. 168 
Even analyses of the federal administrative state that do not use the term 
"democratic deficit" describe the federal administrative state using characteristics that 
are similar to those that exist in countries with democratic deficits. For example, Nina 
Mendelson notes that there is an opaqueness to the operation of administrative agency 
decision-making and that this " .. .lack of adequate transparency has significant adverse 
consequences, both for the appropriateness of presidential influence and for the 
legitimacy of agency decision making." 169 The lack of transparency, as it relates to 
European Union decision-making, has often surfaced in criticisms of the European 
Union. 170 Similarly, from a domestic perspective, a lack of transparency may lead to a 
concern that agency actions suffer from a lack of "legitimacy." 171 In turn, a lack of 
legitimacy can also lead to a lack of accountability as, the more difficult it is to see what 
163 See Marchant, supra note 20, at 256 ("Administrative agencies are required to partake in extensive, 
procedurally time-consuming activities geared toward public participation and judicial review before setting 
final rules - a lengthy, time-consuming effort that is not in harmony with the speed of innovation." (citation 
omitted)). 
164 See Farber & O'Connell, supra note 19, at 1337. 
165 See 5 U.S.C. § 553 (2012); see also Thomas 0. Sargentich, The Critique of Active Judicial Review of 
Administrative Agencies: A Reevaluation, 49 ADMIN. L. REV. 599, 638 (1997) (highlighting "the transparency 
of notice-and-comment rulemaking process "); Seifter, supra note 19, at 1308 ("As the thousands ofregulations 
promulgated each year 'wield[] vast power and touch[] almost every aspect of daily life,' the notice-and­
comment process under section 553 of the Administrative Procedure Act (APA)--the most well-known and 
heralded form of administrative participation, in which interested persons may comment on proposed rules-­
has been celebrated as 'a crucial way to ensure that agency decisions are legitimate, accountable, and just."' 
(citations omitted)). 
166 See Rose-Ackerman, supra note 21, at 439. For more on the concept of "expertise " in administrative law 
and the idea that agencies embody subject-specific expertise over the fields that they regulate, see Seifter, 
supra note 19, at 1325-29. 
167 See Rose-Ackerman, supra note 21, at 436. 
16s Id. 
169 Mendelson, supra note 40, at 1159. 
170 See supra Part III.B. 
171 See Bierschbach & Bibas, supra note 162, at 20; Mendelson, supra note 40, at 1159. 
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has influenced a decision, the more difficult it is to hold an actor (or actors) 
accountable. 172 In sum, analyses of the democratic deficit correspond to analyses of the 
extent to which the goals of administrative law are actually being carried out in the day­
to-day operation of the administrative state. 
The American democratic deficit in ART innovation is also significant because 
without it, it is possible that there is less of a "check" on political concerns that might 
affect an administrative agency's decision-making. 173 The impact of policy (or politics) 
on regulatory decision-making is an issue that is salient in many scientific areas beyond 
AR T.174 There is a concern about "political manipulation of scientific research." 175 
Specifically, the fear is that "political views submerged in the process of executive 
supervision may work themselves out through pressure on an agency to skew its 
scientific or technical findings." 176 
In the realm of FDA regulation, the regulatory history of Plan B, which 
spanned across two Presidential administrations, revealed the extent to which political 
pressure could affect regulatory decisions, especially regulatory decisions that are 
supposed to be made on the basis of safety and efficacy . 177 Plan B, an emergency 
contraceptive that was previously a prescription drug, was accompanied by substantial 
data indicating its safety and effectiveness (along with that of its generic drug 
equivalents), coupled with its suitability for designation as an over-the-counter, instead 
of a prescription dmg. 178 There were many aspects of the FDA's 12-year process of 
converting "Plan B and its generic equivalents" from prescription to over-the-counter 
status that indicated the influence of politics over scientific decision-making, including 
the FDA Commissioner's statement that the FDA would not act in accordance with 
scientific evidence indicating that the drug "should be approved for nonprescription use 
for all females of child-bearing potential" in the "first time the Secretary of HHS had 
ever overruled an FDA decision on an OTC switch." 179 Nonetheless, in a multi-year 
regulatory process, accompanied by a U.S. Government Accountability Office ("GAO") 
report (at the behest of members of Congress concerned about the influence of politics 
over the regulatory process), the purposeful inclusion of individuals with anti-abortion 
172 See Bierschbach & Bibas, supra note 162, at 20 ("A central concept [in administrative law] is participation, 
the idea that citizens should have some input into agency decisions. Public participation, of course, is not the 
only way to check agency abuses. But it is a crucial way to ensure that agency decisions are legitimate, 
accountable, and just. [It also] blend[s] democracy with agency expertise and judicial oversight [along with] 
legitimacy and accountability concerns."); Mendelson, supra note 40, at 1159. 
173 Mendelson, supra note 40, at 1155. 
174 See RESCUING SCIENCE FROM POLITICS: REGULATION AND IBE DISTORTION OF SCIENTIFIC RESEARCH 281-
97 (Wendy Wagner & Rena Steinzor, eds. 2016); Evan J. Criddle, Chevron's Consensus, 88 B.U. L. REV. 
1271, 1287-88 (2008). 
175 Mendelson, supra note 40, at 1143. 
176 Id. at 1144. 
177 See Lisa Heinzerling, The FDA 's Plan B Fiasco: Lessons for Administrative Law, 102 GEO. L. J. 927, 938-
39 (2014) ("Twelve years passed between the petition of private citizens and public health and medical 
organizations to the FD A to approve nonprescription status for levonorgestrel-based emergency 
contraceptives and a court order that the FD A do so . . . .  Much happened during this time . . .  [T] he FD A passed 
through two different presidential administrations. Through it all, the FDA remained steadfast on one point: it 
would not, despite all of the scientific evidence indicating it was the right thing to do, allow unrestricted access 
to all levonorgestrel-based emergency contraception."). 
178 Id.; see Kathryn A Watts, Controlling Presidential Control, 114 MICH. L. REV. 683, 708 (2016) (providing 
the statement of FDA Commissioner Hamburg: "[i]t is our responsibility at FDA to approve drugs that are 
safe and effective for their intended use based on the scientific evidence"). 
179 Heinzerling, supra note 177, at 947-48; Gardiner Harris, Morning After Pill Is Cleared for Wider Sales, 
N.Y. TIMES, Aug. 24, 2006, at A l .  
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perspectives on an FDA Advisory Committee, the resignations of multiple career FDA 
officials, and federal litigation, it became evident that the FDA' s decision to not approve 
the designation of Plan B and similar drugs as an over-the counter-medicine was driven 
by political considerations, including the influence of the "White House and 
'constituents who would be very unhappy with . . .  an over-the-counter Plan B.""180 The 
analysis of these actions also emphasized the "clandestine" attempts of the Executive 
Branch to influence the FDA and the lack of transparency attributed to many FDA 
decisions and processes. 181 While Plan B was eventually approved for over-the-counter 
use, the FDA's inclusion of political views in the regulatory process led to significant 
concern over the independence of the agency and the legitimacy of its decisions. 182 
While the American federal government has had little response to the American 
democratic deficit in ART innovation, the states have responded in connection to 
research issues that often implicate issues related to ART, such as embryo destruction. 
The destruction of embryos in connection with research related to embryonic stem cells 
has led to significant controversy surrounding ART and stem cell research in the United 
States. 183 
Analyses of decision-making in the states have also focused on the existence 
of the "democratic deficit." 184 Those analyses have found that a "democratic deficit" 
also exists in the states, but states are seen as being more responsive to citizen requests 
simply by virtue of the fact that in some states, citizens can participate in referenda and 
ballot initiatives. 185 Additional analyses have also found that in spite of the "democratic 
180 Naomi Cahn & June Carbone, Family Classes: Rethinking Contraceptive Choice, 20 U. FLA. J.L. & PuB. 
POL'Y 361, 382 (2009); Watts, supra note 178, at 708; Alastair J.J. Wood et al., A Sad Day for Science at the 
FDA, 353 N. ENG. J. MED. 1197, 1197-98 (2005); see Heinzerling, supra note 177, at 930-58; see also 
Tummino v. Torti, 603 F. Supp. 2d 519, 523-24, 544-45, 548 (E.D.N.Y. 2009) ("While it may have been 
rational for the FDA to consider adolescent cognitive development in its evaluation of Plan B as an OTC drug, 
plaintiffs have presented unrebutted evidence that the FDA's focus on these behavioral concerns stemmed 
from political pressure rather than permissible health and safety concerns."). 
181 Cahn & Carbone supra note 180, at 381-82; Harris, supra note 179; Watts, supra note 178, at 710-11. 
182 See Watts, supra note 178, at 709 ("Not surprisingly, controversy quickly empted over what the media 
described as Sebelius's 'unprecedented' decision to override the FD A's science-based findings."); see Alastair 
J.J. Wood et al., The Politics of Emergency Contraception, 366 N. ENG. J. MED. 101, 101-102 (2005) ("[W]e 
called attention to the damage that the FD A was doing- both to its reputation as an impartial regulatory agency 
that made decisions on the basis of science, insulated from politics, and potentially to women's health.");. 
183 See Sherley v. Sebelius, 689 F.3d 776, 779 (D.C. 2012) (determining whether federal funding should be 
provided to "research projects directly involving the destruction of a human embryo and projects using 
embryonic stem cells derived from an earlier destruction"); see also Carbone & Cahn, supra note 180, at 1016 
("The status of embryos, which involves profound religious and philosophical differences and which has 
become the subject of entrenched political differences over the course of the abortion fight, lies at the heart of 
these developments."); Jennifer L. Enmon, Stem Cell Research: Is the Law Preventing Progress?, 2002 UTAH 
L. REV. 621, 637-42 (2002) (discussing the debate over the personhood of IVF clinics' excess frozen 
embryos); Sonia M. Suter,In Vitro Gametogenesis: Just Another Way to Have a Baby?, 3 J.L. & BIOSCIENCES 
87, 116-18 (2016) (discussing the issue of embryo destruction in the context of another form of assisted 
reproductive technology, in vitro gametogenesis). 
184 See Future of American Federalism, supra note 43, at 1112 ("Although the United States has not generally 
been thought to suffer from the same sort of 'democratic deficit' that haunts European discourse, we are 
experiencing profound frustration with gridlocked and nonresponsive government in Washington, reflected in 
the precipitous decline in public trust in national governing institutions."). 
185 Miriam Seifter, Further from the People? The Puzzle of State Administration, 93 N.Y.U. L. REV. 107, 146-
47 (2018) ("[S]cholars, courts, and policymakers . . .  tend to agree that states are closer to the people in some 
way that matters. In particular, the traditional praise for proximity suggests that it makes state governments 
more responsive to their constituents' desires or deters abuses of state power, or both." (citations omitted)); 
see The President, Executive Order No. 13132, Federalism (Aug. 4, 1999), 64 Fed. Reg. 43,255, 43,255-56 
(Section 2. "Fundamental Federalism Principles[:] In formulating and implementing policies that have 
federalism implications, agencies shall be guided by the following fundamental federalism principles: (a) 
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deficits" that exist in the state levels, many state legislators are responsive to citizen 
concerns, albeit with certain biases. 186 
The article observes that the process for approving mitochondrial transfer is 
swifter (and more concrete) in the United Kingdom than in the United States because in 
the U.K., the agency responsible for drafting regulations related to the issue conducted 
a public consultation regarding the scientific and ethical issues surrounding the 
procedure.187 In contrast, the United States has avoided using the standard administrative 
legal process and public consultations in general when new ART techniques are at 
issue. 188 While this approach led to innovation in ART in the past, as traditional ART 
developed during the use of a minimally restrictive governance framework, the same 
has not occurred as it relates to ART techniques involving inheritable genetic 
modifications in the United States.189 While there has been an ongoing global discussion 
of the impacts of germline editing and a robust public discussion in the United Kingdom 
of both the impacts of heritable genetic modifications and ART in general, the American 
experience has been marked by a more limited national conversation regarding the 
impacts of ART and heritable genetic modifications. 190 The national conversation has 
largely been limited to a National Academy of Sciences report and conversations among 
employees of the Executive Branch, which includes the FDA, and has failed to include 
the larger American public. 191 Further, funding restrictions implemented by Congress 
Federalism is rooted in the belief that issues that are not national in scope or significance are most appropriately 
addressed by the level of govermuent closest to the people . . . .  (d) The people of the States are free, subject 
only to restrictions in the Constitution itself or in constitutionally authorized Acts of Congress, to define the 
moral, political, and legal character of their lives. (e) The Framers recognized that the States possess unique 
authorities, qualities, and abilities to meet the needs of the people and should function as laboratories of 
democracy."). 
186 See Micah Gell-Redman et al., It's All About Race: How State Legislators Respond to Immigrant 
Constituents, 71 POL. RES. Q. 517, 527-28 (2018); Kim Q. Hill & Jan E. Leighley, The Policy Consequences 
of Class Bias in State Electorates, 36 AM. J. POL. SCI. 351, 363 (1992); but see Seifter, supra note 185, at 146-
50. 
187 2013 ANNUAL REPORT, supra note 83, at 4 ("The dialogue, entitled 'Medical Frontiers: debating 
mitochondrial replacement', was carried out over a period of six months, where we took the public temperature 
on this important and emotive issue. Our consultation showed broad support for mitochondrial replacement 
being made available to families with serious inherited mitochondrial diseases, provided the techniques are 
safe enough to use in the clinic and are well regulated."). 
188 See supra Part IILB. l ;  see also Subterranean Regulation, supra note 5, at 1241-45 (2018) (discussing the 
FD A's issuance of Untitled Letters to providers of forms of assisted reproductive technology involving genetic 
modifications). 
189 See supra Part III; see also Lars Noah, Assisted Reproductive Technologies and the Pitfalls of Unregulated 
Biomedica!Innovation, 55 FLA. L. REV. 603, 617-18 (2003) ("Unlike other medical technologies, AR Ts arrive 
on the scene with little or no rigorous testing of their safety and effectiveness."). 
190 See Jordan Paradise, U.S. Regulatory Challenges for Gene Editing, 13 SCITECH LA WYER 10, 11 (2016); 
International Summit on Human Gene Editing, NAT'L ACADS. OF SCI., ENG'G, & MED., 
http:/ /nationalacademies.org/ gene-editing/Gene-Edit-Summit [https:/ /perma.cc/9 JUF-7 4CX] (" A major 
component of the National Academy of Sciences and the National Academy of Medicine's Human Gene­
Editing Initiative is an international summit that took place December 1-3, 2015, in Washington, D.C. Co­
hosted with the Chinese Academy of Sciences and the U.K.'s Royal Society, the summit convened experts 
from around the world to discuss the scientific, ethical, and governance issues associated with human gene­
editing research."); Second International Summit on Human Gene Editing, NAT'L ACADS. OF SCI., ENG'G, & 
MED., http://www.nationalacademies.org/gene-editing/2nd_summit [https://perma.cc/P6C4- KXZ5]. 
191 See sources cited supra notes 148-50 and accompanying text (discussing the FDA's approach to political 
and social concerns that "have the potential to affect regulatory decisions."); see also NAT'L ACADS. OF SCIS., 
ENG. & MED., MITOCHONDRIAL REPLACEMENT TECHNIQUES: ETHICAL, SOCIAL, AND POLICY 
CONSIDERATIONS 150 (2016). For more on the study approach, see id. at 3, 24; see also R. Alta Charo, Dealing 
with Dolly: Cloning and the National Bioethics Advisory Commission, 38 JURIMETRICS J. 11, 11-14 (1997) 
(discussing the roles of "public bioethics commissions," including presidential bioethics commissions); M. 
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have created an environment in which, even if the hurdle created by the actions of those 
employed by administrative agencies was removed, these techniques would still face 
significant obstacles to federal approval in the U.S. 192 
As a matter of outcome, there are also practical implications to the United 
States' democratic deficit in ART, which has culminated in a restrictive regime that 
hinders access to advanced assisted reproductive technologies. As seen in instances of 
cytoplasmic transfer193 in the United States, when the technique is not available in the 
United States, those with economic means are able to obtain it abroad, like the patients 
of the aforementioned Dr. Zhang who traveled to Mexico in order to obtain 
mitochondrial transfer from a U.S.-based physician in contravention of federal 
restrictions. 194 This response raises the issue of "reproductive tourism." 195 Many 
scholars have noted that FDA approval is often a precursor to insurance coverage of a 
treatment. 196 Further, this is especially relevant in the realm of ART where a small 
number of states mandate coverage of ART services.197 Thus, to the extent that the FDA 
fails (or refuses) to approve these techniques in the United States, it could contribute to 
the gap in healthcare between those who are well-off, and can pursue treatments without 
Cathleen Kaveny, Rhetoric, Public Reason and Bioethics: The President's Council on Bioethics and Human 
Cloning, 20 J.L. & POL. 489, 491-94 (2004); John P. Holdren, Note on Genome Editing, THE WHIIB HOUSE 
OFFICE (May 26, 2015), https://obamawhitehouse.archives.gov/blog/2015/05/26/note-genome-editing 
[https://perma.cc/P4PD-RE7Z] ("The White House fully supports a robust review of the ethical issues 
associated with using gene-editing technology to alter the human germline. The Administration believes that 
altering the human germline for clinical purposes is a line that should not be crossed at this time."). 
192 See Rob Stein, Babies With Genes From Three People Could Be Ethical, Panel Says, NPR (Feb. 3, 2016), 
http://www.npr.org/sections/health-shots/2016/02/03/465319186/babies-with-genes-from-three-people­
could-be-ethical-panel-says [https://perma.cc/T4DZ-AX K7] (discussing the National Academies of Sciences, 
Engineering and Medicine report on cytoplasmic transfer); Statement on NIH Funding of Research Using 
Gene- Editing Technologies in Human Embryos, NAT'L INST. OF HEALTH (Apr. 29, 2015), 
https://www.nih.gov/ about -nih/w ho-we-are/nih-director/ statements/ statement -nih-fuuding-research-using­
gene-editing-techno lo gies-human-embryo s [https:/ /perma.cc/7 KGM-AHV3] (indicating that the NIH will not 
fund any use of gene-editing technologies in human embryos."). While gene editing and mitochondrial 
transfer are different techniques and research involving mitochondrial transfer is arguably further ahead due 
to its actual clinical use in the U.K. (and the use of it by U.S. doctors abroad), the social and ethical issues 
posed by genetic modification exist for both technologies. 
193 Ooplasmic/Cytoplasmic Transfer, C1R. FOR GENETICS & Soc'Y, https://www.geneticsandsociety.org/ 
internal-content/ooplasmiccytoplasmic-transfer [https:/ /perma.cc/UB G9-RP22] ( defining cytoplasmic 
transfer as "an experimental fertility technique that involves injecting a small amount of ooplasm from eggs 
of fertile women into eggs of women whose fertility is compromised. The modified egg is then fertilized with 
sperm and implanted in the uterus of the woman attempting to achieve pregnancy."). 
194 See Zhang, supra note 116 and accompanying text. 
195 See Lisa C. Ikemoto, Reproductive Tourism: Equality Concerns in the Global Market for Fertility Services, 
27 J. L. & INEQUALITY 277, 277-79 (2009) (discussing the practice of"reproductive tourism," and those who 
travel to access fertility treatments); Kimberly M. Mutcherson, Welcome to the Wild West: Protecting Access 
to Cross Border Fertility Care in the United States, 22 CORNELL J. L. & PUB. POL'Y 349, 349-50 (2012) 
(discussing "cross border fertility care"). 
196 See, e.g., Rachel E. Sachs, De/inking Reimbursement, 102 MINN. L. REV. 2307, 2309, 2314-21 (2018) 
("Although there is not always perfect agreement between the set of FDA-approved drugs and the drugs payers 
are required to cover, in general there is significant overlap. Particularly for public payers, this robust coverage 
of prescription drugs is required by federal law. Although private payers are often less constrained, many of 
them provide similarly comprehensive prescription drug coverage pursuant to federal and state laws."). 
197 See King, supra note 27, at 313 n.142 (discussing access to assisted reproductive technologies, disparities 
in access to ART, and states that mandate insurance coverage of ART); Falloon & Rosoff, supra note 157, at 
63-64 (discussing barriers to access to assisted reproductive technology that exist even with insurance 
coverage). 
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insurance coverage, and those who cannot. 198 As such, under this democratic deficit, 
disparities continue to exist not only with respect to the experience of U.S. patients as 
compared to those in other countries, but also with respect to experiences of patients 
within the United States, where some patients will be able to travel to access innovations 
in ART and others will not. 199 
States have also enacted legislation related to embryonic stem cell research, 
with some states encouraging it, and others banning it.200 As a matter of funding, in 
response to actions at the federal level that have precluded innovation by limiting the 
availability of research funding, some states, like California, have used representative 
democracy to identify state goals for innovation, such as the California Institute for 
Regenerative Medicine which was created after a referendum201 and New York's Empire 
State Stem Cell Trust Fund which was created through State Finance Law. 202 State 
coverage of stem cell research is relevant because it implies that there was some 
democratic input into the funding process at the state level whereas at the national level, 
the Executive and Legislative Branches (through budget riders) tend to exercise control 
over research funding involving techniques that are accompanied by ethical 
controversy.203 The New York Stem Cell Fund has contributed to research related to 
mitochondrial transfer.204 In turn, this state-funded research has contributed to the 
international discourse on ART techniques involving inheritable modifications. 205 In 
other words, where there is limited federal funding, the private sector and states may 
respond in furtherance of innovation. 
198 See Judith F. Daar, Accessing Reproductive Technologies: Invisible Barriers, Indelible Harms, 23 
BERKELEY J. GENDER L. & JUST. 18, 22, 31-32, 36-39 (2008) (discussing political, socioeconomic, and racial 
barriers to accessing assistive reproductive treatment). 
199 See I. Glenn Cohen, Circumvention Tourism, 97 CORNELL L. REV. 1309, 1311-12, 1323-26 (2012) 
(discussing "medical tourism" in the context of assisted reproductive technology, in addition to 
"circumvention tourism," a subset of medical tourism). 
200 Enmon, supra note 183, at 641-4 7 ( discussing various state statutes affecting embryonic stem cell research). 
201 About CIRM, CAL. INST. FOR REGENERATIVE MED. (2018), https://www.cirm.ca.gov/ 
[https://perma.cc/QG7T-F5XH]. 
202 Frequently Asked Questions About NYSTEM, N.Y. STATE, https://stemcell.ny.gov/node/191 
[https://perma.cc/Y3TX-9LEH]. For more on state stem cell initiatives, see CONGRESSIONAL RESEARCH 
SERV., STEM CELL RESEARCH: STATE INITIATIVES 2-8 (2006), 
https://stemcells.nih.gov/staticresources/research/GW-State-Funding.pdf; State Initiatives for Stem Cell 
Research, NAT'L INST. OF HEALTH, https://stemcells.nih.gov/research/state-research.htm 
[https://perma.cc/CS82-9FKJ]. 
203 See Sebelius, 689 F.3d at 780 (discussing the role of Presidents George W. Bush and Barack Obama in 
providing guidance to the National Institutes of Health on the funding of stem cell research); see also 
Calandrillo & Deliganis, supra note 77, at 313. 
204 See Jeff Lyon, Sanctioned UK Trial of Mitochondrial Transfer Nears, 317 JAMA 462, 463 (2017) ("The 
HFEA hesitated last summer when major players in the drive to bring MRT to fruition published work that 
included some qualms. The first article last June in Cell Stem Cell described an in vitro experiment in which 
Dieter Egli, PhD, and his colleagues at the New York Stem Cell Foundation sought to determine what happens 
to the minute amount of maternal mtDNA that inevitably hitches a ride when researchers create an embryo 
with the mother's nDNA and the donor's healthy mtDNA."). 
205 Id. Additionally, just as states have provided funding of stem cell research in the absence of governmental 
funding, private organizations (including professional organizations) have also provided funding for assisted 
reproductive technology research. See Am. Soc. for Reproductive Med., American Society for Reproductive 
Medicine Announces Major Research Initiative- Creation of the ASRM Research Institute, a $10 Million 
Startup Investment for the Future of Reproductive Medicine, ASRM BULLETIN (Jun. 12. 2018), 
https://www.asrm.org/news-and-publications/news-and-research/press-releases-and-bulletins/american­
society-for-reproductive-medicine-annonnces-major-research-
initiative/? _ga=2.228771932. l l 4 722499 .1545121639-l 132316020.1545121639 [https://perma.cc/CAA2-
8R5L ]. 
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The U.S. experience with ART, primarily at the federal level, highlights the 
lack of transparency and public participation in the administrative process even though 
the administrative legal process was structured to further these goals. 206 As a result, 
states are making up for the lack of public participation in federal administrative law. 207 
The next section crafts solutions based on a number of disciplines, notably 
administrative law and health law, to the American democratic deficit in ART 
innovation. 
V. ADAPTING THE TOOLS OF ADMINISTRATIVE LAW TO MINIMIZE 
THE U.S. DEMOCRATIC DEFICIT IN ASSISTED REPRODUCTIVE 
TECHNOLOGY INNOVATION 
The solutions in this section could minimize the American democratic deficit 
in ART and also hasten the implementation of forms of ART involving genetic 
modification. These recommendations draw on scholarship in administrative law and 
examples of successful approaches, including the UK's experience with mitochondrial 
transfer and state experiences with stem cell research funding and legislation. Part A 
examines and critiques the possibility of an independent federal agency in the United 
States that would regulate ART use, whereas parts B-D examine the UK's five-strand 
public discourse on mitochondrial transfer and methods of adapting public discourse 
into the American administrative state. 
A. AN INDEPENDENT FEDERAL AGENCY IN THE U.S. 
While other scholars have argued for an independent federal agency 
to regulate ART, this article does not advocate for that approach. 208 Many of the scholars 
who do advocate for an independent federal agency build on the example of the 
HFEA.209 Yet, despite the similarities between the United States and the United 
Kingdom, many differences between the two would make the creation of such an 
independent federal agency addressing ART both unlikely and unfeasible. First, 
religious opposition to ART and the medical industry's general opposition to increased 
regulation would make it difficult to create such an agency.210 Second, logistically, even 
206 See Bierschbach & Bibas, supra note 162, at 23 ("Participation . . .  enhances the soundness of agency 
decisions by improving the quality and variety of the information an agency considers, whether empirical or 
related to the public's preferences. It improves accountability by obligating agencies to justify their actions 
publicly . .  .It increases public trust and educates citizens in government affairs, creating feedback loops 
between agencies and citizens. And, . . .  it bolsters agency decision-making's democratic pedigree." ( citations 
omitted)); Marchant, supra note 20, at 256. 
207 See Nina Mendelson, A Presumption Against Agency Preemption, 102 NW. U. L. REV. 695, 709 (2008) 
("Second, federalism, including a state's enactment of its own laws, also may stimulate citizen participation in 
self-governance, on the theory that it is easier to participate at a level of government closer to one's home."); 
but see Frank Cross, The Folly of Federalism, 24 CARDOZO L. REV. 1, 1-2 (2002) (suggesting that "federalist" 
values are really values of localism). While much of the administrative law scholarship focuses on 
administrative law at the national level, states also have administrative agencies. For more on state 
participation in the federal administrative law process and the implementation of federal programs, see 
generally, Seifter, supra note 155. For more on the operation of administrative law at the state level, see 
Michael Asimow, Contested Issues in Contested Cases: Adjudication Under the 2010 Model State 
Administrative Procedure Act, 20 WIDENER L.J. 707, 707-13 (2011); Seifter, supra note 185, at 131-48; 
Michael Asimow, The Influence of the Federal Administrative Procedure Act on California's New 
Administrative Procedure Act, 32 TuLSA L. J. 297, 298-303 (1996); Seifter, supra note 185, at 131-48 .. 
208 See King, supra note 27, at 169-70. 
209 See id. at 169 (referring to "the HFEA indications approach"). 
210 Robert Gatter, Faith, Confidence, and Health Care: Fostering Trust in Medicine Through Law, 39 WAKE 
FOREST L. REV. 395, 440 (2004); William M. Sage & David A Hyman, Combating Antimicrobial Resistance: 
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if such an agency was created, significant effort would likely have to be exerted in order 
to figure out how that agency and the FDA, which has been regulating ART involving 
genetic modification and the drugs and devices used in ART treatments would share 
jurisdiction, if at all. Additionally, if funding restrictions imposed by Congressional 
budget riders continued to exist, then an HFEA-like agency would have to decide how 
the National Institutes of Health would fit into the regulatory framework. Further, an 
independent federal agency would still remain subject to political pressure and 
budgetary control by Congress and the President.211 Additionally, while Congress could 
introduce an act to seize power from the states, who have regulated ( or failed to regulate, 
depending on one's point of view) ART, giving the federal govermnent more power 
over reproductive issues (and by implication, reproductive rights and the practice of 
medicine), this in general does not resolve the issue of who should be regulating ART. 
Additionally, from the perspective of strengthening reproductive rights (or maintaining 
the status quo), is likely undesirable. 212 Beyond that, the myriad of issues surrounding 
ART, especially in a country that has failed to have a national public discourse on 
traditional ART, would not be resolved by the creation of an HFEA-like agency. 
B. ADAPTING THE UK'S PUBLIC CONSULTATION ON ASSISTED REPRODUCTIVE 
TECHNOLOGY TO THE U.S. REGULATORY REGIME 
Many aspects of the UK's public consultation on mitochondrial transfer would 
fit into the United States' existing federal regulatory framework governing ART. Just as 
notice-and-comment rulemaking can improve public participation in the administrative 
process, so can other methods of promoting the inclusion of public views in the agency 
regulatory process.213 In fact, many of the aspects of the UK's public consultation on 
mitochondrial transfer are similar to actions that the HHS has already undertaken for 
other issues.214 
For example, when determining the meaning of essential health benefits, the 
HHS allowed individual states to set that benchmark. 215 Before issuing the document 
that announced this decision, HHS undertook a number of methods of outreach with 
Regulatory Strategies and Institutional Capacity, 84 TuL. L. REV. 781, 815 (2010) (discussing self-regulation 
in healthcare); but see John A. Robertson, Assisted Reproductive Technology and the Family, 47 HASTINGS 
L.J. 911, 920 (1996) (noting that the American Society for Reproductive Medicine would be amenable to an 
HFEA-like agency that would license and inspect fertility clinics, whereas the author, Professor John 
Robertson, is skeptical of the creation of such an agency); Robertson, supra note 24, at 1035-36 ("With 
adequate peer involvement, more explicit legal controls, such as the national licensing authority suggested in 
the Warnock Report, need not take root in American soil."). 
211 Kirti Dada & Richard L. Revesz, Deconstructing Independent Agencies (and Executive Agencies), 98 
CORNELL L. REV. 769, 808, 816 (2013); Neal Devins, Regulating of Governmental Agencies Through 
Limitations Riders, 1987 DUK.E L. J. 456, 461 (discussing "appropriations as oversight"). 
212 See King, supra note 27, at 173 (detailing the "five main functions" of a proposed "national independent 
regulatory body . . .  which would include at least two functions that would infringe on the practice of medicine: 
" l )  establish a licensing system for ART clinics; 2) establish procedural guidelines and regulations for ART 
practice; . . .  5) in the case that proven risks outweigh the benefits for certain procedures, regulate the use of 
PGS for certain indications using the novel balancing framework proposed above."); see also Cahn & Carbone, 
supra note 180, at 380 (discussing "how politics at the national level can affect access to reproductive rights"). 
213 Bierschbach & Bibas, supra note 162, at 20. 
214 See HHS Agencies & Offices, U.S. DEP'T OF HEALTH & HUMAN SERVS. (Oct. 27, 2015), 
https://www.hhs.gov/about/agencies/hhs-agencies-and-offices/index.html [https:/ /perma.cc/S3 2Y -UK7V] 
("HHS has 11 operating divisions, including eight agencies in the U.S. Public Health Service and three human 
services agencies."); id. (noting that the FDA is an operating division within the U.S. Department of Health 
and Human Services). 
215 Nicholas Bagley & Helen Levy, Essential Health Benefits and the Affordable Care Act: Law and Process, 
39 J. HEALTH POL., POL'Y, & L. 441, 442, 447-49 (2014). 
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states and other stakeholders, including the public with whom the agency interacted 
through "a series of 'listening sessions. "'216 Professors Bagley and Levy note that HHS 
had no obligation to undertake such an inclusive approach under the Administrative 
Procedure Act's notice-and-comment requirements.217 Yet, such an inclusive process 
would greatly improve the regulation of advanced assisted reproductive technologies in 
the United States. Granted, the example of deciding what would be included in the term 
"minimum essential health benefits" is not a perfect parallel to ART innovation. While 
it is likely that ethical and political views on reproduction and women's health surfaced, 
those ethical views were not the same as those involved in regulating traditional ART 
and advanced assisted reproductive technologies. 218 Nonetheless, the format of these 
"listening sessions" could be used in public discourse related to a number of other 
health-related issues, including ART. 
The listening sessions held by HHS are similar to the second and third strands 
of the UK's public consultation, which included face-to-face interviews with members 
of the public.219 As it is, U.S. administrative agencies already conduct "public meetings" 
in which they explain regulatory decisions; therefore, the structure for something 
analogous to the second strand of the UK's public consultation already exists. 
Additionally, agencies are staffed by scientific (and technical staff). Thus, agencies 
already employ individuals who, like those who provided explanations to members of 
the public of the science underlying mitochondrial transfer in the first strand of the UK 
public consultation, could explain to the American public the techniques involved in 
mitochondrial transfer.220 The FDA, for example, already has a "Grand Rounds" 
program in which FDA scientists "present[] on a key public health challenge and how 
FDA is applying science to its regulatory activities."221 The FDA could expand this 
Grand Rounds Program and expand its format into the agency's public meetings, were 
it to participate in a public discourse on mitochondrial transfer. 
Another option is to increase the visibility of the array of ethical and social 
viewpoints on ART in order to address the current situation in which the positions of 
politicians have been serving as proxies for the viewpoints of members of the American 
public. The current point of reference in the U.S. for ethical issues related to new forms 
of ART is driven by the feelings or beliefs of politicians and employees in the federal 
legislative and executive branches, yet no one has asked the American public whether it 
has an opinion on forthcoming medical innovations and their perrnissibility.222 These 
216 Id. at 445, 449. 
217 Id. ("The agency had no obligation to do any of this public outreach. Without informing anyone of its 
thinking, HHS could simply have issued a notice of proposed mlemaking annonncing the benchmark 
approach. After receiving comments and issuing a final rule, HHS would then have complied with all of the 
AP A's notice-and-comment requirements."); id. at 456 (noting that "agencies do not have to solicit feedback 
on guidance documents."). 
218 Cf Burwell v. Hobby Lobby, 573 U.S. 682 (2014). Thus, while ethical views may not have prevented the 
inclusion of contraception in minimum essential health benefits at the level of the administrative agency's 
decision making, the ethical views, which would be religious views in the Hobby Lobby case, of those who 
would be subsidizing the insurance plans required to have minimum essential health benefits are entitled to a 
certain amonnt of exemption or waiver by the federal government. 
219 See FDA Grand Rounds, U.S. FOOD & DRUG ADMIN. (Dec. 20, 2018), 
https ://www.fda.gov/ scienceresearch/ aboutscienceresearchatf da/ucm4 86 711. htm [https :/ /perma. cc/9LN G-
W GXH]. 
220 See supra note 105 and accompanying text (explaining the first strand of the U K's public consultation on 
mitochondrial transfer). 
221 See FDA Grand Rounds, supra note 219. 
222 Stein, supra note 192 ("But [Dr.] Sauer said he was disappointed when he learned of the FD A's response. 
'Politics as usual often gets in way of progress," Sauer said in a subsequent email. While the FDA statement 
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political feelings or beliefs manifest not only through public statements, but also 
regulatory actions that have not been subject to judicial review, such as funding 
restrictions, budget riders and non-interpretive documents issued by administrative 
agencies. 223 As such, another option could be to use mlemaking to address the issue of 
federal regulation of ART using a rule instead of informal documents, as doing so could 
also facilitate the deliberative public process that is currently missing in the federal 
regulation of ART.224 
In 2016, Professor Barbara Evans wrote that "[i]t is time to insist on evidence­
based bioethics."225 Again, the UK's public consultation could serve as a model for the 
United States. For example, the UK asked members of the public what their views were 
on the ethical considerations related to mitochondrial transfer and then tracked whether 
their views changed after the concept was further explained to them. 226 Implementing 
something similar in the United States would be a way to institute evidence-based 
bioethics. 227 Considering the role of states, outside of the bioethics literature other 
professors have noted that "experimentation may help clarify the ideological space."228 
In the area of stem cell research, state involvement has already created an experimental 
ideological space where state laws and funding decisions are proxies for the views of 
the public.229 At the federal level, using patient focus groups, for example, as the UK 
did in the fifth strand of their public consultation, would allow members of the public to 
provide input on the "moral, ethical, and social policy issues related to genetic 
modification of eggs and embryos . . .  that . . . have the potential to affect regulatory 
decisions. 230 
C. GREATER DISCLOSURE: SEPARATING SCIENTIFIC CONCERNS FROM POLITICAL 
AND ETHICAL CONCERNS 
Many scholars have written in favor of more disclosure and transparency 
within the administrative law and health law literatures.231  Professor Nina Mendelson, 
["prais[ ed] the 'thoughtful work' of the panel and said the agency would be 'reviewing' the recommendations 
of the 2016 Institute of Medicine Panel] . . .  [since then] . . .  the latest federal budget 'prevents the FDA from 
using funds to review applications in which a human embryo is intentionally created or modified to include' 
changes that could be passed down to future generations . . .  any such research 'cannot be performed in the 
United States' at this time"]."] . . .  [This] would cause 'undue delays' in his research, he added that he hoped 
it wouldn't permanently 'necessarily halt the efforts."'). 
223 See FDA Letter, supra note 119 (noting that the FDA had jurisdiction over the mitochondrial replacement 
techniques used by Dr. John Zhang and also noting that, pursuant to the Consolidated Appropriations Act, the 
FDA could not use "funds to accept IND submissions for clinical itNestigations that involve 'a human embryo 
. . .  intentionally created or modified to include a heritable genetic modification."'). 
224 See Aaron L. Nielson, Sticky Regulations, 85 U. CHI. L. REV. 85, 88, 94 (2018). 
225 Barbara J. Evans, The Evolving Ethics Challenge in Genomic Science, 13 SCITECH LA WYER I, 24 (2016). 
226 See supra Part III. 
227 Evans, supra note 225. 
228 Michael Livermore, The Perils of Experimentation, 126 YALE L. J. 636, 674 (2017) ("But for new policy 
domains- for example, when stem cell research first arose as a policy question- experimentation may help 
clarify the ideological space."); see id. at 674 n.118 ("Clarifying ideological space may be of value to society, 
depending on how that information is put to use. Even if the clarification is not socially valuable, it might still 
be valuable to political actors."). 
229 See Nefi D. Acosta & Sidney H. Golub, The New Federalism: State Policies Regarding Embryonic Stem 
Cell Research, J. LAW MED. & ETHICS 419, 419 (2016). 
230 MEETING #59 TRANSCRIPT, supra note 148, at 13; see sources cited supra note I l l  and accompanying 
text (providing the fifth strand of the UK's public consultation on mitochondrial donation). 
231 See Evan J. Criddle, Fiduciary Administration: Rethinking Popular Representation in Agency Rulemaking, 
88 TEX. L. REV. 441, 478 (2010) (discussing the value of transparency in administrative law); Elizabeth Y. 
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for example, has argued for greater disclosure of the role of executive supervision in 
agency decisions. 232 One hope is that greater disclosure of the role of executive or 
political pressure in agency decisions might lead to a more deliberative democracy 
where agency employees disclose to what extent their views are, as evidenced by for 
example, the FDA' s decisions related to the prescription over-the-counter switch of Plan 
B, actually based on safety and efficacy and not factors outside of the agency's statutory 
mandate, such as political pressure.233 Further, a significant amount of the FDA's 
decision-making process occurs outside of the public's view and "documents exchanged 
between the FDA and a drug sponsor during the back-and-forth over a new drug 
application are not made public, often not even after the application is approved."234 In 
other words, to the extent that political pressures, moral concerns, or social policy views 
are being incoiporated into the decision-making process, they should be disclosed. 235 
This article takes a similar approach as, in the realm of assisted reproduction, scientific 
and social concerns often overlap, even though the FDA is an agency that is supposed 
to regulate for safety and effectiveness. 236 For example, in the realm of cloning (which 
is not an ART, as it does not so much involve reproduction as replication), the FDA 
stated that not only did the procedure require an investigational new drug application, 
but also that the FDA would not accept any applications due to unresolved safety 
concerns, yet the agency did not identify those concerns. 237 In the instance of the FD A's 
original failure to approve Plan B for use in all women of childbearing age, the agency 
seemed to also muddle social concerns with safety concerns.238 The FDA has undertaken 
a similar approach to forms of ART involving genetic modification. For example, with 
respect to cytoplasmic transfer, the FDA reportedly told one researcher, who engaged 
with them after receiving a letter stating that the technique would require an 
investigational new drug application, that the researcher would have to prove that the 
technique was safe.239 The agency could not, however, tell the researcher what studies 
McCuskey, Agency Imprimatur & Health Reform Preemption, 78 OHIO ST. L.J. 1059, 1162 (2017) ("The 
agency imprimatur model has the potential to imbue health law federalism decisions with more transparency 
and public participation opportunities than judicial preemption decisions afford."). 
232 Mendelson, supra note 40, at 1130-31, 1163-65, 1169. 
233 James T. O'Reilly, Losing Deference in the FDA 's Second Century: Judicial Review, Politics, and a 
Diminished Legacy of Expertise, 93 CORNELL L.REV. 939, 964-67 (2008); Watts, supra note 178, at 732. 
234 Heinzerling, supra note 177, at 938. 
235 Mendelson, supra note 40, at 1130-31, 1163-65. 
236 21 U.S.C. § 393(b)(2) (2012). 
237 See Subterranean Regulation supra note 5, at 1257, 1292-93 (providing FDA's view on the regulation of 
human cloning in the United States); see also, Therapeutic Cloning and Genome Modification, Cellular & 
Gene Therapy Products, U.S. FOOD & DRUG ADMIN. (Mar. 16, 2018), 
https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/ucm2007205 .htrn ("In March 
2001, FD A sent a letter to the research community asserting regulatory authority over clinical research using 
cloning technology to create a human being, and to advise that FDA regulatory process is required in order to 
initiate these investigations. FDA jurisdiction includes human cells used in therapy involving the transfer of 
genetic material by means other than the union of gamete nuclei. Examples of such genetic material include, 
but are not limited to: cell nuclei (for cloning), oocyte nuclei, ooplasm, which contains mitochondria and 
genetic material contained in a genetic vector, transferred to gametes or other cells. Any clinical research 
involving these techniques would require an IND."). 
238 Wood et al., supra note 180, at 1197-98 ("The stated reason is that there is uncertainty about the drug's 
safety in younger women. But the FDA has not pointed to any data support that position, nor has the agency 
demanded such evidence in the case of other drugs that have been switched to over-the-counter status. All 
involved acknowledge that Plan B is extraordinarily safe."). 
239 Counor, supra note 6 (noting that FDA employees could not tell him what he needed to do in order to 
establish safety and that the "animal literature established, as well as you can establish, safety . . .  [as such] . 
168 AMERICAN JOURNAL OF LAW & MEDICINE VOL. 45 NO. 2-3 2019 
would be required in order to prove that the technique was safe. 24° Considering the 
FD A's statutory mandate, which is to evaluate products for safety and effectiveness, the 
agency should be able to articulate to prospective applicants what would satisfy its 
interpretation of the safety and effectiveness requirements of its enabling statute. 241 Not 
doing so causes the public to question "the integrity of the [regulatory] process," and for 
those in the medical profession, "[i]t is also likely to mean that both physicians and 
patients will wonder whether future drug-approval decisions are based on the evidence 
with regard to efficacy and safety or, rather, on, political considerations. How will we 
know? How will we find out?" 242 
These concerns regarding the integrity of the regulatory process undermine 
administrative law's goals of accountability and legitimacy. 243 While the public was able 
to ascertain the existence of decision-making outside of the statutory mandate in the 
instance of Plan B, it required federal litigation (that included discovery beyond what 
the public would have been able to obtain through Freedom of Information Act requests) 
and a GAO report.244 The experience of the FDA in regulating other forms of ART 
involving genetic modification indicates that it is possible that the FDA continues to 
succumb to political and social pressures in the regulatory process, yet the public lacks 
an opportunity to ascertain whether that is the case. Increasing the use of deliberative 
democracy in the decision-making process would increase the opportunity for the public 
to ascertain what underlies the agency's decision-making and also, to the extent that 
political or social views are being considered in the regulatory process, create an 
environment for a more thorough and fair consideration of social and political views, 
with transparency. 
In light of the UK's robust analysis of the underlying safety and effectiveness 
of mitochondrial transfer, using the UK's five-strand consultation could aid the FDA in 
separating its safety analysis from its social analysis. 245 Drawing from the UK's analysis 
would allow the FDA to categorize exactly which aspects of its regulatory decision­
making corresponds to (1) safety, (2) effectiveness, and (3) political, social, and ethical 
considerations. For example, the public consultation in the UK revealed that many 
individuals' concerns surrounded the safety of the techniques and that "[s]ometimes, 
safety concerns become a proxy for concerns about ethical and social issues, which are 
often hard to express. On other occasions, support for mitochondria replacement dipped 
when the scientific evidence was less clear."246 In the leadup to the approval of 
mitochondrial transfer in the United Kingdom, the HFEA conducted multiple reviews 
of the scientific and safety issues related to the use of mitochondrial transfer, where it 
examined the existing medical literature and current research, including that of U.S.­
based scientists. 247 The example of the UK's approval of mitochondrial transfer, which 
included a safety and scientific review, in addition to a public consultation and an 
assessment of social and ethical considerations, indicates that safety and science 
. you can never say 'it's safe' until you do it."); see supra note 104 and accompanying text (providing the 
similar view of the UK's Chief Medical Officer on the use of mitochondrial transfer in humans). 
24° Connor, supra note 6. 
241 21 U.S.C. § 393(b)(2) (2012). 
242 See Jeffrey M. Drazen et al., The FDA, Politics, and Plan B, 350 N. ENG. J. MED. 1561, 1561-62 (2004); 
Wood et al., supra note 180, at 1199. 
243 See Drazen et al., supra note 242, at 1561 (20040; Watts, supra note 179, at 708, 726. 
244 Heinzerling, supra note 177, at 952. 
245 See ADVICE TO GOVERNMENT, supra note 93, at 7. 
246 Id. at 15. 
247 See infra Part III; see also supra note IO I and accompanying text (citing to the UK's four publications on 
the science and safety of mitochondrial transfer). 
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analyses can be separated from ethical, social, and political concerns. Applying the 
lessons of the U .K. 's experience with the approval of mitochondrial transfer, the FD A 
should clearly state which aspects of current and forthcoming ART and advanced 
assisted reproductive technologies implicate scientific concerns and which aspects 
implicate social, political, and ethical considerations. 
D. INCREASING THE ROLE OF THE STATES 
States have instituted a number of measures that address the deficit in 
deliberative democracy related to stem cell research and ART in the United States. 
Increasing the role of the states in the regulation of traditional ART and advanced 
assisted reproductive technologies flows naturally from the jurisdiction of states and 
their responses to democratic deficits in the regulatory process in the United States to 
date. As a jurisdictional matter, states already have historic police powers that empower 
them to serve as gatekeepers to the medical profession. 248 Additionally, states have 
regimes to compensate citizens for certain harms suffered during medical treatment 
through tort regimes that provide for medical malpractice liability. 249 Beyond creating 
liability regimes for damages incurred during medical treatment, states have also 
instituted regimes that recognize the results of ART use, whether of parentage or leftover 
embryos, through family law statutes and court decisions.25° Further, as a matter of 
funding, some states fund research that the federal government will not, with an 
emphasis on research that involves the destruction of embryos. 251 At the same time, 
states have created statutory regimes that indicate what kind of research they will fund, 
with some states funding types of research that Congress would not and other states 
creating regimes with restrictions that are very similar to federal limitations.252 
Nonetheless, the benefit of these state regimes is that they allow for more democratic 
participation by, at the very least, clearly signaling to the public that lawmakers are 
undertaking decisions related to these matters. 
For those states that do choose to fund research and innovation that has been 
stymied by Congress, it could be useful for them to take on a stronger role in the 
gathering of information related to innovations in ART or medicine in general. For 
example, a common refrain of scientists whose research involves genetic modification 
is that society needs to decide whether it is desirable to undertake scientific innovations 
that involve inheritable genetic modifications. 253 This is notable not only because it is a 
deviation from the often-undertaken effort of scientists and physicians to regulate 
themselves, but also because it represents a call by innovators to include societal views 
in science.254 Currently, the national government has failed to undertake this 
conversation, but states are well-placed to do so as an alternative to the current 
regulatory standstill in the absence of discourse, by virtue of their proximity to 
citizenry.255 Not only might states want to undertake this consultation on their own, but 
248 See BARRYFuRROW ET AL., HEALIBLAW: CASES, MATERIALS, AND PROBLEMS 87 (7th ed. 2013). 
249 See Daar, supra note 17, at 615. 
250 See id. at 624-26, 646; but see Courtney G. Joslin, Protecting Children(?): Marriage, Gender, and Assisted 
Reproductive Technology, 83 S. CAL. L. REV. 1177, 1178-81 (2010). 
251 See Alicia Ouellette et al., Lessons Across the Pond: Assisted Reproductive Technology in the United 
Kingdom and the United States, 31 AM. J. L. & MED. 419, 423, 436-37 (2005). 
252 See id. at 423. 
253 See, e.g., Mary T. Bergman, Perspectives on Gene Editing, HARVARD GAZETTE (Jan. 9, 2019), 
https :/ /news.harvard. edu/ gazette/ story /20 19/01/perspectives-on-gene-editing/ [https :/ /perma. cc/3 CFZ-3 3 6E]. 
254 Id. 
255 Seifter, supra note 185, at 146-47. 
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the federal government should consider whether it should actively encourage states to 
do so, as increasing the participation of states in the regulatory regime might not only 
encourage public involvement in the regulatory process, but also allow for 
experimentation. 256 
VI. CONCLUSION 
The article has focused on the American democratic deficit in ART and how 
states have made strides in correcting that deficit. For decades, the political discourse 
has remained at a standstill as legislators have refused to address questions related to the 
ethics of ART, especially those involving germline modification. Furthermore, those 
legislators have refused to address those questions through several actions including: (1) 
spending restrictions on applications that would involve such processes, (2) refusing to 
check administrative agency overreach, in spite of media and literature coverage, and 
(3) the disbanding of bioethics commissions. 
While ethics certainly matter, the question of whether they should impact 
regulatory decision-making, instead of being left to the doctor-patient relationship 
(assuming all patient protections such as informed consent and patient protective 
bioethics principles exist), is a question for another article.257 Also, to the extent that 
there is a concern in the United States as to partisan politics affecting health care, 
individual rights, and science more broadly, expanding the use of democratic inputs, 
especially as it relates to federal decision-making that implicates reproductive rights, 
reproductive healthcare, and ultimately the ability of parents to decide what is best for 
their future children, adopting the solutions provided in this article might " . . .  not only 
produce more effective policy but also increase the acceptability of the regulatory 
process."258 Doing so would have implications not only for the administrative state, but 
also for the American public's impressions of the administrative state and the role of the 
federal government in affecting their everyday lives. 
256 While states currently license medical providers, another question that might be asked is whether the current 
demarcation of state and federal jurisdiction should remain as it is, especially in the realm of advanced assisted 
reproductive technologies. That normative issue is a topic for another paper. See Bagley, supra note 7, at 271 
("Even though regulation of health and safety is 'primarily, and historically, a matter of local concern,' there 
is no question that the Federal Government can set uniform national standards in these areas."(citations 
omitted)). 
257 See, e.g., King, supra note 27, at 107 (advocating "for the creation of an independent federal entity, the 
Assisted Reproductive Technology Authority (ARTA)"). 
258 Rose-Ackerman, supra note 21, at 442. 
